Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche. A literature review to inform the evidence base for incretin focussed pharmacology in the metabolic liver diseases space and an informed commentary on unmet areas of need. Incretin-based therapeutics demonstrate multifarious benefits across the chronic metabolic disease spectrum with promising data across the continuum of pathology.
Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George
Clin Mol Hepatol 2024;30(3):436-448. Published online April 16, 2024
Background/Aims The global proportion of hepatocellular carcinoma (HCC) attributable to metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. The MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction, irrespective of concurrent liver disease. We aimed to determine the total global prevalence of MAFLD in HCC cohorts (total-MAFLD), including the proportion with MAFLD as their sole liver disease (single-MAFLD), and the proportion of those with concurrent liver disease where MAFLD was a contributary factor (mixed-MAFLD).
Methods This systematic review and meta-analysis included studies systematically ascertaining MAFLD in HCC cohorts, defined using international expert panel criteria including ethnicity-specific BMI cut-offs. A comparison of clinical and tumour characteristics was performed between single-MAFLD, mixed-MAFLD, and non-MAFLD HCC.
Results 22 studies (56,565 individuals with HCC) were included. Total and single-MAFLD HCC prevalence was 48.7% (95% confidence interval [CI] 34.5–63.0%) and 12.4% (95% CI 8.3–17.3%), respectively. In HCC due to chronic hepatitis B, C, and alcohol-related liver disease, mixed-MAFLD prevalence was 40.0% (95% CI 30.2–50.3%), 54.1% (95% CI 40.4–67.6%) and 64.3% (95% CI 52.7–75.0%), respectively. Mixed-MAFLD HCC had significantly higher likelihood of cirrhosis and lower likelihood of metastatic spread compared to single-MAFLD HCC, and a higher platelet count and lower likelihood of macrovascular invasion compared to non-MAFLD HCC.
Conclusions MAFLD is common as a sole aetiology, but more so as a co-factor in mixed-aetiology HCC, supporting the use of positive diagnostic criteria.
Citations
Citations to this article as recorded by
Astragaloside IV alleviates metabolic associated fatty liver disease by regulating ferroptosis via the SLC7A11/GPX4 pathway Sitong CHEN, Hanying XU, Zipei ZHANG, Xiaonan LI, Xiaolei TANG, Dashi YING Chinese Journal of Analytical Chemistry.2026; 54(2): 100625. CrossRef
Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Clinical Gastroenterology and Hepatology.2026; 24(6): 1644. CrossRef
Obstructive sleep apnea is associated with greater MASH and significant fibrosis severity in patients with obesity: A prospective clinicopathological study Jia Feng, Wenhui Chen, Zunhao Zhang, Fuqing Zhou, Yang Liu, Zhirui Qiu, Yan Liu, Zhiyong Dong, Cunchuan Wang, Hao Wang, Yi Ma Diabetes, Obesity and Metabolism.2026; 28(3): 1972. CrossRef
Rising burden of MASLD and CKM syndrome in Asia: A decade of trends and future projections Tianqi Duo, Yun Wen, Yu Bian, Yizheng Wang, Xiaofang Zhang, Jin Ju, Yanjie Lu, Zhiguo Wang, Jinghao Wang, Baofeng Yang Metabolism.2026; 178: 156549. CrossRef
Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study Yaxuan He, Yu Cao, Zekai Chen, Rong Xiang, Fang Wang Scientific Reports.2026;[Epub] CrossRef
Comparison of patients with HCC with and without MASLD after surgical resection Chia-Jung Ho, Hao-Jan Lei, Chun-Ting Ho, Gar-Yang Chau, Shu-Cheng Chou, Elise Chia-Hui Tan, Pei-Chang Lee, Yi-Hsiang Huang, Ying-Ying Yang, Teh-Ia Huo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su JHEP Reports.2026; 8(4): 101768. CrossRef
Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection Talal K Bhatti, Joseph K Lim World Journal of Gastroenterology.2026;[Epub] CrossRef
Comparison of the efficacy of transarterial chemoembolization combined with radiofrequency ablation or sintilimab and bevacizumab for unresectable hepatocellular carcinoma Tingting Li, Hongyi Zhao, Chengbin Dong, Yang Song, Miaomiao Li BMC Gastroenterology.2026;[Epub] CrossRef
Integrative Multiomics Analysis Reveals the Ameliorative Effects of Astragalus membranaceus Extract on Metabolic Dysfunction-Associated Steatotic Liver Disease Jiayi An, Yi Li, Zunhan Zhang, Yaru Chang, Guanxiu Xiao Molecules.2026; 31(7): 1120. CrossRef
Noncanonical function of epigenetic reader YTHDF1 inhibits MASLD progression by maintaining peroxisomes and mitochondrial homeostasis Chenyang Mu, Jian Tan, Yuefan Wang, Haozan Yin, Zhihui Dai, Zenghan Wang, Dongyang Ding, Zhichao Zhang, Sijie Wang, Hui Liu, Fu Yang Experimental & Molecular Medicine.2026; 58(4): 1172. CrossRef
Integrating machine learning and spatial transcriptomics uncovers shared immunomodulatory deubiquitinases in MAFLD and HCC Yu-xi Han, Hongze Li, Wendi Xia, Junyi Ma, Jiaqi Zhang, Yiling Li Human Genetics.2026;[Epub] CrossRef
Role of the NF-κB signaling pathway in vascular endothelial cell injury associated with metabolic dysfunction-associated steatotic liver disease under hypoxia Jingxuan Zhang, Chenguang Zhang, Chao Yang, Yongjun Miao, Xiaomeng Wei, Zijian Zhang, Zihan Shen, Guodan Bao Biochemical and Biophysical Research Communications.2026; 817: 153710. CrossRef
Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach Beom Kyung Kim The Kaohsiung Journal of Medical Sciences.2026;[Epub] CrossRef
Association Between Uric‐Acid‐to‐HDL Ratio and Hepatic Steatosis Diagnosed by Liver Ultrasound Transient Elastography Lili Chu, Meng Wu, Bo Zhang, Jinger Lu, Ying Chen, Zhiwen Luo International Journal of Clinical Practice.2026;[Epub] CrossRef
Risk factors for non-alcoholic fatty liver disease in pregnant women as a basis for in-depth examination and prevention of obstetric complications Elena V. Mozgovaya, Marina A. Kryshnia Journal of obstetrics and women's diseases.2026; 75(2): 42. CrossRef
Reply to “Enhancing Capsule on Liver CT: Implications for Steatotic Liver Disease” Se Jin Choi, Dong Hwan Kim, Jae Ho Byun American Journal of Roentgenology.2026;[Epub] CrossRef
Valerenic acid attenuates chronic stress-exacerbated metabolic dysfunction-associated steatotic liver disease via the estrogen receptor α-GDF15 axis Xingli Wu, Yuzi Jiang, Junmin Wang, Simin Gu, Yanping Wang, Ning Li, Chunmei Qian, Hongming Nie, Yiyuan Zheng, Yong Li European Journal of Pharmacology.2026; 1030: 179106. CrossRef
Traditional Chinese Medicines for Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Mixed‐Method Systematic Review Zhipeng Wei, Liping Guo, Guohua Zhang, Yicheng Qian, Zhou Lan, Kehu Yang Journal of Evidence-Based Medicine.2026;[Epub] CrossRef
Association of the Number of Concurrent Metabolic Syndrome Risk Factors with Textbook Outcomes Following Liver Resection for Patients with Hepatocellular Carcinoma: A Multicenter Study Zhan-Cheng Qiu, Jun-Long Dai, Yu Zhang, Fei Xie, Yu Yu, Shu-Sheng Leng, Tian-Fu Wen, Chuan Li Annals of Surgical Oncology.2025; 32(1): 399. CrossRef
Deciphering the roles of neddylation modification in hepatocellular carcinoma: Molecular mechanisms and targeted therapeutics Wenxin Wu, Xuanyi Wang, Ruijie Ma, Shuhong Huang, Hongguang Li, Xinxing Lyu Genes & Diseases.2025; 12(4): 101483. CrossRef
Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma Rongfei Fang, Chunxiu Sha, Qun Xie, Dengfu Yao, Min Yao Anti-Cancer Agents in Medicinal Chemistry.2025; 25(2): 75. CrossRef
Associations of MAFLD subtypes and air pollutants with multi-system morbidity and all-cause mortality: A prospective cohort study Jingyi Zhang, Shanshan Ran, Shengtao Wei, Fei Tian, Lan Chen, Zijun Yang, Ge Chen, Hualiang Lin Ecotoxicology and Environmental Safety.2025; 291: 117893. CrossRef
Global burden and international disparities in NASH-associated liver Cancer: mortality trends (1990–2021) and future projections to 2045 Qilong Nie, Yongwen Jiang, Mingyang Li, Qiuyan Liang, Xiaoai Mo, Tengyu Qiu, Qunfang Jiang, Kaizhou Huang, Youqing Xie, Ying Chen, Xiaojun Ma, Jianhong Li, Kaiping Jiang Frontiers in Public Health.2025;[Epub] CrossRef
Exploring emerging frontiers in hepatology: iLIVER's continuing journey Ming-Da Wang, Xin-Fei Xu, Lei Cai, Tian Yang iLIVER.2025; 4(1): 100148. CrossRef
A review of image guidance and localization methods for liver puncture robots Yongde Zhang, Jiabin Yang, Xuequan Huang, Chuang He Journal of Robotic Surgery.2025;[Epub] CrossRef
Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon Liver International.2025;[Epub] CrossRef
Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis Sahana Shetty, Renuka Suvarna, Vanessa Ambrose Fistus, Shivam Modi, Joseph M Pappachan World Journal of Hepatology.2025;[Epub] CrossRef
Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma: a retrospective cohort study Shadi Zerehpooshnesfchi, Fatema Safri, Ziyan Pan, Romario Nguyen, Lawrence Yuen, Vincent Lam, Christopher Nahm, Tony Pang, Golo Ahlenstiel, Jacob George, Mohammed Eslam, Liang Qiao Therapeutic Advances in Chronic Disease.2025;[Epub] CrossRef
Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide Yuki Oe, Takashi Omori, Eriko Aimono, Shin Furukawa, Hirohiko Kitakawa, Masatoshi Tateno, Kiyoshi Sakai, Kyu Yong Cho Frontiers in Endocrinology.2025;[Epub] CrossRef
Trends and visualization analysis of research on MASLD-Related hepatocellular carcinoma: a bibliometric analysis Hongkun Yin, Xusheng Zhang, Qi Wang Discover Oncology.2025;[Epub] CrossRef
Overweight and Helicobacter pylori infection: a correlation in metabolic dysfunction-associated fatty liver disease Xu Chen, Jiayue Fu, Kejia Jin, Zixuan Yang, Yidan Qian, Kehan Mei, Yihan Wang, Jialei Min, Yilin Du, Zaisheng Zhu, Shengcun Li Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Hemostatic alterations in metabolic dysfunction-associated steatotic liver disease (MASLD) and their link to venous thromboembolism (VTE) David E. González-Mendoza, Francisco Fernández-Nogueira, Misael Uribe, Norberto C. Chávez-Tapia, Natalia Nuño-Lámbarri Thrombosis Research.2025; 253: 109395. CrossRef
Rewriting the MASLD‐associated hepatocellular carcinoma script: Targeting epigenetics and metabolism Chiara Aiello, Eric Felli, Teresa Musarra, Lorenzo Nevi, Annamaria Altomare, Jordi Gracia‐Sancho, Andrea Baiocchini, Simone Carotti International Journal of Cancer.2025; 157(10): 1991. CrossRef
Role of mac-2 binding protein glycosylation isomer in predicting fibrosis in patients with metabolic dysfunction-associated steatotic liver disease Thuy Thi Thu Pham, Dat Tan Ho, Chanh Pham, Hoan Phan, Bieu Phu, Toan Nguyen, Dang Nguyen, Hai Thanh Phan, Khue Minh Nguyen World Journal of Hepatology.2025;[Epub] CrossRef
The triadic relationship between nonalcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease: From molecular mechanisms to clinical management Yuxi Jin, Mohammed Alissa, Ahmed Ezzat Ahmed, Amin A. Al-Doaiss, Naif Asiri, Yasser Assiri, Shahid Ullah Khan, Munir Ullah Khan, Samuel Joseph Current Problems in Cardiology.2025; 50(11): 103170. CrossRef
Exploring the Link Between Irritable Bowel Syndrome and Chronic Diseases: A Narrative Overview Sneha Reddy, Savithri C. Veluri Academic Medicine & Surgery.2025;[Epub] CrossRef
Fibrosis Severity in MASLD Determines the Predictive Value of Lp-PLA2 for Carotid Atherosclerosis in Type 2 Diabetes: A Cross-Sectional Study Junzhao Ye, Rui Song, Xiaorong Gong, Xin Li, Congxiang Shao, Bihui Zhong Biomedicines.2025; 13(10): 2431. CrossRef
Lipid metabolism in cancer cells: Its role in hepatocellular carcinoma progression and therapeutic resistance Tin Lok Wong, Yanshu Kong, Stephanie Ma Hepatology Communications.2025;[Epub] CrossRef
Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova GASTROENTEROLOGY.2025; 59(3): 206. CrossRef
Protective effect and mechanisms of puerarin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of animal studies Xiang-yun Zou, Yu-cheng Yang, Xue-han Liu, Wen-ying Qi, Xiao-bin Zao, Xiao-ke Li, Yong’an Ye Pharmacological Research.2025; 222: 108024. CrossRef
A comprehensive bibliometric and visual analysis of tumor-associated macrophages in hepatocellular carcinoma GuanBo Zhang, Gang Li, JinSong Li, Jie Zhang, Zhi Yang, Lin Yang, ShiJie Jiang, ShiFan Zhu, JiaXing Wang Discover Oncology.2025;[Epub] CrossRef
Targeting Ferroptosis: New Insights and Therapeutic Advances in MAFLD Complicating T2DM Fang Yao, Gaochao Wang, Fan Ning, Yanbo Shi Frontiers in Bioscience-Landmark.2025;[Epub] CrossRef
Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing Xixi Fang, Chenhao Xu, Jun Lu, Runzhou Zhuang, Xiao Xu, Xuyong Wei Cell Biochemistry and Function.2025;[Epub] CrossRef
Glucagon‐Like Peptide‐1 Receptor Agonists and Hepatocellular Carcinoma Prevention: A Meta‐Analysis and Clinical Decision Framework Andrea Dalbeni, Marco Vicardi, Leonardo Antonio Natola, Filippo Cattazzo, Alessandra Auriemma, Rosa Lombardi, Felice Cinque, Luca Dalle Carbonare, Alessandro Mantovani, David Sacerdoti Cancer Medicine.2025;[Epub] CrossRef
Mechanistic roles and intervention strategies involving gut microbiota, amino acid metabolism, and the tumor immune microenvironment in MAFLD-HCC progression Ziwei Guo, Ziang Yao, Xiaohan Chen, Dongjie Wu, Yaqi Ouyang, Yaocun Shen, Yi Wang, Houyan Zhang, Yanping Lu, Wenliang Lv Clinical and Experimental Medicine.2025;[Epub] CrossRef
Splanchnic inflammatory syndrome and the not-so-silent risk of cancer Richard C Semelka MD, Miguel Ramalho MD Gastroenterology & Hepatology: Open access.2024; 15(3): 63. CrossRef
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef
Unraveling the epidemiology of metabolic dysfunction-associated liver cancer: Insights from mixed etiologies, regional variations, and gender disparities Gong Feng, Ya-Fei Fan, Ru-Xin Li, Giovanni Targher, Christopher D. Byrne, Ming-Hua Zheng iLIVER.2024; 3(3): 100113. CrossRef
Impact of occult hepatitis B virus infection and high-fat diet on hepatocellular carcinoma development Kun Chen, Chunfeng Qu Hepatoma Research.2024;[Epub] CrossRef
Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research Maito Suoh, Saeed Esmaili, Mohammed Eslam, Jacob George Hepatology International.2024; 18(6): 1740. CrossRef
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 965. CrossRef
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis Muhammed Shabil, Mahalaqua Nazli Khatib, Suhas Ballal, Pooja Bansal, Balvir S. Tomar, Ayash Ashraf, M. Ravi Kumar, Aashna Sinha, Pramod Rawat, Abhay M. Gaidhane, Sanjit Sah, Afukonyo Shidoiku Daniel, Ambanna Yappalparvi, Ganesh Bushi BMC Endocrine Disorders.2024;[Epub] CrossRef
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K. H. Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L. Chan, Min Hepatology International.2024; 18(6): 1661. CrossRef
Dietary ω-3 polyunsaturated fatty acid intake improves skeletal muscle mass in patients with metabolic dysfunction-associated fatty liver disease: A nationwide cross-sectional study Li-Zhan Bie, Chao Wu, Jia-Lu Wang World Journal of Hepatology.2025;[Epub] CrossRef
Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care Zobair M. Younossi, Vincent Wai‐Sun Wong, Emmanuel A. Tsochatzis, Laurent Castera, Michael Betel, Linda Henry, Shira Zelber Sagi Liver International.2025;[Epub] CrossRef
Steatotic liver disease, MASLD and risk of chronic kidney disease Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher Diabetes & Metabolism.2024; 50(1): 101506. CrossRef
Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka European Journal of Gastroenterology & Hepatology.2024; 36(4): 430. CrossRef
Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice Paul N Brennan, Oliver D Tavabie, Wenhao Li, Thomas Marjot, Lynsey Corless, Jonathan A Fallowfield, Helen Jarvis, Dina Mansour, Stuart McPherson, William Rosenberg, Karen Rockell, Jeremy Tomlinson, Andrew Yeoman, Emmanuel A Tsochatzis, John F Dillon, Will The Lancet Gastroenterology & Hepatology.2024; 9(6): 577. CrossRef
Does an Aspirin a Day Take the MASLD Away? Amedeo Lonardo, Ming-Hua Zheng Advances in Therapy.2024; 41(7): 2559. CrossRef
Neuroimmune modulation in liver pathophysiology Ju Zou, Jie Li, Xiaoxu Wang, Daolin Tang, Ruochan Chen Journal of Neuroinflammation.2024;[Epub] CrossRef
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease” Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon Clinical and Molecular Hepatology.2023; 30(1): 118. CrossRef
“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer to fatty liver disease related to systemic metabolic dysregulation. The name change from nonalcoholic fatty liver disease (NAFLD) to MAFLD comes with a simple set of criteria to enable easy diagnosis at the bedside for the general medical community, including primary care physicians. Since the introduction of the term, there have been key areas in which the superiority of MAFLD over the traditional NAFLD terminology has been demonstrated, including for the risk of liver and extrahepatic mortality, disease associations, and for identifying high-risk individuals. Additionally, MAFLD has been adopted by a number of leading pan-national and national societies due to its concise diagnostic criterion, removal of the requirement to exclude concomitant liver diseases, and reduction in the stigma associated with this condition. The current article explores the differences between MAFLD and NAFLD diagnosis, areas of benefit, some potential limitations, and how the MAFLD terminology has opened up new fields of research.
Citations
Citations to this article as recorded by
Racial Disparities in Mortality Rates among Patients with Hepatic Steatosis, Non-Alcoholic Fatty Liver Disease, and Non-Alcoholic Steatohepatitis: Insights from NHANES III Data Shahrzad Bazargan-Hejazi, Cameron Hines, Myra Usmani, Chris Argueta, Deyu Pan, Arleen F. Brown Journal of Racial and Ethnic Health Disparities.2026; 13(2): 1083. CrossRef
Managing Nonalcoholic Fatty Liver Disease Through Structured Lifestyle Modification Interventions Andrew Thomas, Annie Thomas American Journal of Lifestyle Medicine.2026; 20(3): 463. CrossRef
Serum uric acid/creatinine ratio and metabolic-associated fatty liver disease risks in children Bi Chen, Xiaoning Qu, Ting Li, Minghua Jiang Pediatric Research.2026; 99(2): 728. CrossRef
Prevalencia e importancia de la enfermedad periodontal en pacientes con enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD) en Veracruz L. Roesch-Ramos, D.N. Guzmán-Uzcanga, S. Nolasco-Polito, S. Pérez-Pérez, F. Moreno-Marín, R.M. Francisco, H.R. Ordaz-Álvarez, F.B. Roesch-Dietlen, J.M. Remes-Troche, A.D. Cano-Contreras Revista de Gastroenterología de México.2026; 91(1): 19. CrossRef
Gut microbiota as a metabolic mediator to prevent or attenuate MASLD Jing Luo, Yijiang Wei, Zhexin Fan, Baokun Li, Lingzhi Li, Yiwei Chai, Zihan Xing, Yingying Qiu, Wenwei Lu, Zhifeng Fang Critical Reviews in Food Science and Nutrition.2026; 66(7): 1446. CrossRef
Astragaloside IV alleviates metabolic associated fatty liver disease by regulating ferroptosis via the SLC7A11/GPX4 pathway Sitong CHEN, Hanying XU, Zipei ZHANG, Xiaonan LI, Xiaolei TANG, Dashi YING Chinese Journal of Analytical Chemistry.2026; 54(2): 100625. CrossRef
Associations between per- and polyfluoroalkyl substances and metabolic dysfunction-associated steatotic liver disease in adolescents and young adults: modifying roles of age, lifestyle factors, and PNPLA3 genotype Shiwen Li, Jiawen Carmen Chen, Elizabeth Costello, Douglas I. Walker, Jesse A. Goodrich, Lily Dara, Lucy Golden-Mason, Ana C. Maretti-Mira, Scott M. Bartell, Veronica M. Vieira, Tanya L. Alderete, Michael I. Goran, Zhanghua Chen, Frank D. Gilliland, Britt Environmental Research.2026; 288: 123320. CrossRef
Assessment of the Diagnostic Performance and Clinical Impact of AI in Hepatic Steatosis: Systematic Review and Meta-Analysis Jiamei Song, Dan Liu, Jitong Li, Haoru Cong, Ruixue Deng, Yihan Lu, Jiayi Sun, Jingzhou Zhang Journal of Medical Internet Research.2026; 28: e78310. CrossRef
A multicenter trial to test pitavastatin calcium in youth with combined dyslipidemia of obesity: Design, implementation, challenges, and responses Sarah D. de Ferranti, Jessica E. Teng, Silva A. Arslanian, Andrew M. Atz, Julie A. Brothers, Mark J. Cartoski, D’Andrea R. Freemon, Sheela N. Magge, William T. Mahle, Michele Mietus-Snyder, Amy Peterson, Geetha Raghuveer, Mark W. Russell, Amy S. Shah, Cra American Heart Journal.2026; 294: 107327. CrossRef
Leucine Alleviates Endoplasmic Reticulum–Stress Mediated Lipotoxic Injury Induced by High-Fat Diet Via Sar1b/Sestrin2/Ampkα1 Pathways in Acanthopagrus Schlegelii Wenli Zhao, Yuedong Shen, Xuan Wang, Yangguang Bao, Óscar Monroig, Tingting Zhu, Xie Shichao, Peng Sun, Douglas R Tocher, Qicun Zhou, Min Jin The Journal of Nutrition.2026; 156(2): 101258. CrossRef
A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma J. M. John Britto, T Beula Bell Irish Journal of Medical Science (1971 -).2026; 195(2): 1051. CrossRef
Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases Huiting Che, Yidan Gao, Yonghu Xu, Hui Xu, Roland Eils, Mei Tian Signal Transduction and Targeted Therapy.2026;[Epub] CrossRef
Prevalence and importance of periodontal disease in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Veracruz L. Roesch-Ramos, D.N. Guzmán-Uzcanga, S. Nolasco-Polito, S. Pérez-Pérez, F. Moreno-Marín, R.M. Francisco, H.R. Ordaz-Álvarez, F.B. Roesch-Dietlen, J.M. Remes-Troche, A.D. Cano-Contreras Revista de Gastroenterología de México (English Edition).2026; 91(1): 19. CrossRef
Subtype-specific associations of steatotic liver disease with gastric and esophageal cancers: a nationwide cohort study Yeo Wool Kang, Minkook Son, Jong Yoon Lee, Sang Yi Moon, Myeongseok Koh Gastric Cancer.2026; 29(2): 365. CrossRef
Gpx4 Deletion‐Mediated Macrophage Ferroptosis Alleviates Obesity‐Associated Insulin Resistance Suhua Wu, Juan Peng, Xiaodong Wang, Hong Gao, Huangrui Fang, Shiyi Hu, Qiufen Wei, Yuanye Dang, Haixia Tu, Mingyan Zhu, Jianye Peng, Yumiao Liu, Gaofeng Zeng, Xiaoyan Dai The FASEB Journal.2026;[Epub] CrossRef
Combination of GLP-1 receptor agonist and Akkermansia muciniphila Akk11 reduces adiposity and ameliorates MASLD in T2D mice Kaige Gao, Zaifei Yin, Chi Zhang, Zixuan Dong, Runqi Wang, Qian Chen, Xiangpeng Liu, Caifeng Jiang, Yalin Wang, Bin Guo, Zhengyu Zhou, Zhihao Jia, Hong Sun, Yu Feng Cell & Bioscience.2026;[Epub] CrossRef
Choline Deficiency Drives the Inflammation–Fibrosis Cascade: A Spatiotemporal Atlas of Hepatic Injury from Weeks 6 to 10 Shang Li, Guoqiang Zhang, Xiaohong Li, Xu Zhao, Axi Shi, Qingmin Dong, Changpeng Chai, Xiaojing Song, Yuhui Wei, Xun Li Antioxidants.2026; 15(1): 110. CrossRef
Using Large Language Models to Predict Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Proof-of-Concept Analysis Basile Njei, Nelvis Njei, Sarpong Boateng, Omar Al Ta'ani, Yazan Al-Ajlouni Cureus.2026;[Epub] CrossRef
Network Pharmacology-Based Investigation of the Mechanism of Liupao Tea Polyphenol Extract in Preventing MAFLD via the Hepatic EGFR–AKT Pathway Jirui Wei, Xiaozheng He, Tingting Shi, Xiayu Jin, Jun Huang, Qingyao Du, Junda Huang, Tao Li, Xunjie Xie, Yuxin Huang, Chengtao Nie, Yiqi Fan, Xixiao Yang, Luyao Song, Waijiao Tang Journal of Agricultural and Food Chemistry.2026; 74(6): 5359. CrossRef
Procyanidin B2 and an autochthonous apple pulp extract modulate oxidative stress and PPARγ expression on an in vitro model of lipid steatosis in HepG2 cells Adrián Millán-Laleona, Marta Lopez-Yus, Silvia Lorente-Cebrián, Jose M. Arbones-Mainar, Carlota Gómez-Rincón, Víctor López Journal of Physiology and Biochemistry.2026;[Epub] CrossRef
The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease Ioannis Tsomidis, Angeliki Tsakou, Argyro Voumvouraki, Elias Kouroumalis Biomedicines.2026; 14(1): 151. CrossRef
Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study Yaxuan He, Yu Cao, Zekai Chen, Rong Xiang, Fang Wang Scientific Reports.2026;[Epub] CrossRef
Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities Houda Zoubiri, Wassila Saiah, Amel Otmane, Hamza Saidi, Mohamed Makrelouf, Samir Ait Abderrhmane, Ali El Mahdi Haddam, Elhadj-Ahmed Koceir International Journal of Molecular Sciences.2026; 27(3): 1218. CrossRef
Mediating role of metabolic dysfunction-associated fatty liver disease in the association between individual-level noise exposure and liver enzymes in Chinese automotive manufacturing workers Sijia Ou, Jiaheng Yu, Zhaoqian Chen, Yanmei Ruan, Xing Rong, Zejin Ou, Yuxia Zhang, Haijuan Huang, Jiaxin Cui, Zhi Wang International Archives of Occupational and Environmental Health.2026;[Epub] CrossRef
Efficacy of selected dietary supplements and pharmacological agents on metabolic and oxidative stress outcomes in metabolic dysfunction–associated fatty liver disease (MAFLD): a Bayesian network meta-analysis Yunyi Yang, Xiaoli He, Jiayuan Cai, Xiaoxiao Qu, Shufa Tan, Jiawen You, Yanming He, Zheng Yao, Hongjie Yang Frontiers in Pharmacology.2026;[Epub] CrossRef
Efficacy and safety of lower-carbohydrate dietary patterns for metabolic associated fatty liver disease: evidence from randomized controlled trials with grade analysis Yunhang Chu, Ming Yang, Qi Meng, Delong Cong, Lingyu Xu, Peng Dai, Ziqiang Chen, Sulan Chen, Rui Zhang, Yan Leng Nutrition & Metabolism.2026;[Epub] CrossRef
Risk Assessment for Carotid Atherosclerosis in Asymptomatic Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Hana Park, Ji Young Lee, Sungwon Park, Hyo Jeong Lee, Suh Eun Bae, Jaeil Kim, Hye-Sook Chang, Jaewon Choe, Hye Won Park, Ju Hyun Shim Gut and Liver.2026; 20(1): 125. CrossRef
Research on the Therapeutic Effect and Mechanism of Stir-Roasted Deer Velvet Antler with Ghee on Non-Alcoholic Fatty Liver Disease Xuan He, Yinghan Liu, Shuning Cui, Zhenming Yu, Zhongmei He, Ying Zong, Weijia Chen, Jianan Geng, Jia Zhou, Zhuo Li, Yan Zhao, Hongbo Teng Nutrients.2026; 18(3): 401. CrossRef
Hepatoprotective Ergostane and Lanostane Derivatives from Mushrooms for the Management of Metabolic Dysfunction-Associated Fatty Liver Disease: A Review
K.Razak Deen, S. Rithick, M. Muthumari, D. Jayakumar, N. Amrith Sam, K. Balakrishna, Perumal Pandikumar, Savarimuthu Ignacimuthu International Journal of Medicinal Mushrooms.2026; 28(2): 1. CrossRef
Fecal microbiota transplantation alleviates steatosis and inflammation in high-fat and high-sugar diet-induced fatty liver in mice Fangxia Mi, Jinglu Guo, Wentao Zheng, Jianwei Shen, Hua Ye Frontiers in Cell and Developmental Biology.2026;[Epub] CrossRef
Kaempferol reprograms pro-inflammatory macrophage polarization by targeting the PTGS2-PGE2 axis: A multi-omics deconvolution of a traditional anti-inflammatory herb pair Han Chen, Shuying Chen, Haixia Huang, Kai Chen, Huimin Wan, Ruifen Zhang, Linya Wu, Qifang Wu, Haibin Tong, Gang Xu Biochemical Pharmacology.2026; 248: 117865. CrossRef
Building a gene editing lexicon: a model for rare and inherited disorders Leonard A. Valentino, Cedric Hermans, Donna Coffin, Wolfgang Miesbach, Maria Elisa Mancuso, Carmen Unzu, Micheala Jones, David E. Gutstein, William McKeown, Craig M. Kessler Gene Therapy.2026; 33(3): 310. CrossRef
Exploring the link between metabolic dysfunction-associated fatty liver disease and subclinical hypothyroidism in adolescents: a comprehensive review Xinlong Hu, Wenzai Shi, Guoshuai Xu, Wenqiang Li, Nan Yao, Guoyong Yu, Jun Qu Frontiers in Pediatrics.2026;[Epub] CrossRef
Metabolic and liver stiffness measures for hepatocellular carcinoma risk stratification after viral eradication in chronic hepatitis C Sheng-Hung Chen, Hsueh-Chou Lai, Wei-Fan Hsu, Hung-Wei Wang, Cheng-Yuan Peng Journal of the Formosan Medical Association.2026;[Epub] CrossRef
Discovery of a pyrimidine-based steroidal FXR agonist for the treatment of metabolic dysfunction-associated steatotic liver disease Xiaomin Zheng, Zhe Zhang, Xuwen Jiao, Mao Mu, Ang Liu, Yao Huang, Weiping Wu, Chuanrong Liao, Yuhui Jiang, Weiyang Liang, Shan Li, Jing Li, Lei Zhang Bioorganic Chemistry.2026; 174: 109721. CrossRef
Risk factors of coronary artery disease in metabolic-associated fatty liver disease: a single center cross-sectional study Rui Jin, Xumin Wang, Tao Xu, FenFang Zhang, Lei Li Frontiers in Cardiovascular Medicine.2026;[Epub] CrossRef
Rising burden of MASLD and CKM syndrome in Asia: A decade of trends and future projections Tianqi Duo, Yun Wen, Yu Bian, Yizheng Wang, Xiaofang Zhang, Jin Ju, Yanjie Lu, Zhiguo Wang, Jinghao Wang, Baofeng Yang Metabolism.2026; 178: 156549. CrossRef
Uric Acid in Metabolic Dysfunction‐Associated Steatotic Liver Disease Rong Wang, Zhenyu Liu, Jun Lin, Weijing Zhang, Xianzhi Liu, Tong Zhang Portal Hypertension & Cirrhosis.2026; 5(2): 189. CrossRef
Systems Biology Approach to Unraveling Transcriptomic Mechanisms of Ganfule Capsules in Ameliorating Nonalcoholic Fatty Liver Disease Yu Pan, Yunkun Zhang, Suren R. Sooranna, Xiaonan Yang, Yaqin Zhou, Lu Chen, Fei Xu, Danna Huang Combinatorial Chemistry & High Throughput Screening.2026; 29(2): 207. CrossRef
Structured Exercise Interventions and Hepatic–Metabolic Outcomes in Adults with MASLD: A Narrative Review of Randomized Controlled Trials Tuva Marie Lindstad, Shirin Pourteymour, Sindre Lee-Ødegård, Christian André Drevon, Frode Amador Norheim International Journal of Molecular Sciences.2026; 27(7): 2941. CrossRef
Lipid metabolism-MAFLD crosstalk: mechanisms and therapy Bojia Li, Shengai Piao, Yin Fu, Qiang Fu, Peiyao Qin, Weitai Kong, Yidi Ma, Zhe Zhang, Xue Fang, Xiaoyang Hu Frontiers in Endocrinology.2026;[Epub] CrossRef
Creatinine clearance rate predicts all-cause and cardiovascular mortality in patients with MASLD: a Shanghai cohort study Yingqi Hou, Yanqiu Huang, Chenghao Zhang, Wen Gu, Yadan Xu, Shuli Li, Jugang Wu, Jibin Liu, Honglin Liu Frontiers in Medicine.2026;[Epub] CrossRef
PRC1 promotes MAFLD progression by regulating glycolysis/lactylation axis and forming a positive feedback loop Xinlei Zou, Nan Wang, Canghai Guan, Jianjun Gao, Wujiang Shi, Chengru Yang, Shaowu Bi, Tianjie Zhang, Xiangyu Zhong The Journal of Nutritional Biochemistry.2026; 154: 110378. CrossRef
The improvement effect of tea catechins on metabolic diseases: pharmacology and mechanism Yinghao Wang, Wenyuan Peng, Qi Wang, Kunyi Liu, Qiying Zhou Beverage Plant Research.2026;[Epub] CrossRef
The association between ceramide levels and hepatic steatosis severity in metabolic dysfunction-associated fatty liver disease Rui Yang, Jinjiang Xu, Furong Zhao, Xiaoyu Sun, Ying Li, Yalian Zhang, Huijuan Peng, Ling Ding, Bin Guo Clinica Chimica Acta.2026; 589: 121015. CrossRef
Polyvascular subclinical atherosclerosis differs across metabolic dysfunction-associated fatty liver disease subtypes: a community-based cross-sectional study Kui Chen, Lei Liu, Juan Li, Zhongyang Hu, Yanhui Lin, Shuwen Deng, Saiqi Yang, Yaqin Wang, Changfa Wang Nutrition, Metabolism and Cardiovascular Diseases.2026; : 104753. CrossRef
Opportunities and challenges in controlling metabolic dysfunction-associated steatotic liver disease: Editorial on “Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation” Jian Xu, Gang Shi, Tao Sheng, Jingdong Li Clinical and Molecular Hepatology.2026; 32(2): 919. CrossRef
Phyllanthus niruri niosomes ameliorate obesity-induced hepatic steatosis in rats via modulating MALAT1/miR-206/GLP-1R signaling and hepatic lipid metabolism Safaa I. Khater, Mohamed M. A. Hussein, Saydat S. Abdel-Magied, Marwa M. Lotfy, Tarek khamis, Sahar Abdelaziz, Mahmoud Mostafa, Noha Osama El-Shaer, Mahran Mohamed Abd El-Emam Biological Research.2026;[Epub] CrossRef
Discrimination of Steatotic and Non-Steatotic Chemicals Through Transcriptome Analysis in Primary Human Hepatocytes Christina A. Cramer von Clausbruch, Marcha Verheijen, Giulia Callegaro, Jonathan H. Freedman, Rita Ortega-Vallbona, Martina Palomino-Schätzlein, Florian Caiment, Carsten Weiss International Journal of Molecular Sciences.2026; 27(9): 3825. CrossRef
Exogenous 8-hydroxydeoxyguanosine prevents liver fibrosis through the regulation of Rac1-NADPH oxidase signaling in a metabolic dysfunction-associated steatohepatitis model Yoonseok Lee, Ik Soo Kim, Joo Won Kim, Min Kyoung Kim, Yoon Gi Chae, Cheol Soo Choi, Oh Sang Kwon, Yun Soo Kim, Ju Hyun Kim, Dong Hae Chung, Seung Kak Shin Free Radical Research.2026; : 1. CrossRef
Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis Anna Negroni, Luisa Pieroni, Noemi Fiaschini, Francesca Palone, Mariateresa Mancuso, Roberta Vitali PROTEOMICS – Clinical Applications.2026;[Epub] CrossRef
Knowledge, attitude, and practice towards fatty liver disease among the general population in Shanghai, China: a community-based cross-sectional study Xue Yang, Hui Chang, Limei Feng, Bin Wang Frontiers in Public Health.2026;[Epub] CrossRef
Chronic Kidney Disease in Urban, Adult Sri Lankans: A Cohort Follow‐Up Study Shamila De Silva, Dileepa Ediriweera, Madunil Niriella, Anuradhini Kasturiratne, Arunasalam Pathmeswaran, Norihiro Kato, Rajitha Wickramasinghe, H. Janaka de Silva, David Kershaw International Journal of Nephrology.2026;[Epub] CrossRef
Cardiometabolic risk factors in patients with metabolic dysfunction-associated fatty steatotic liver disease: a multicenter study PROMASLD O.M. Drapkina, A.F. Sheptulina, E.O. Liusina, A.S. Demianova, V.D. Lunkov, I.N. Tikhonov, N.I. Trofimovskaya, T.I. Melikov, S.V. Mityukova, E.A. Kovalovskaya Russian Journal of Preventive Medicine.2026; 29(5): 44. CrossRef
Experimental Rodent Models of Metabolic Dysfunction-Associated Fatty Liver Disease: Present Status and Future Perspective Kamlesh K. Bhopale, Mukund P. Srinivasan Livers.2026; 6(3): 45. CrossRef
Single-Nucleotide Polymorphisms in Genes Associated with Mitochondrial and DNA Damage Response Modulate the Risk of Non-Alcoholic Fatty Liver Disease in Humans Sylwia Ziółkowska, Marcin Kosmalski, Łukasz Kołodziej, Kinga Jarmusz, Magdalena Ejsmont, Tadeusz Pietras, Aleksandra Jabłkowska, Maciej Jabłkowski, Janusz Szemraj, Piotr Czarny International Journal of Molecular Sciences.2026; 27(11): 4854. CrossRef
Association Between Uric‐Acid‐to‐HDL Ratio and Hepatic Steatosis Diagnosed by Liver Ultrasound Transient Elastography Lili Chu, Meng Wu, Bo Zhang, Jinger Lu, Ying Chen, Zhiwen Luo International Journal of Clinical Practice.2026;[Epub] CrossRef
Electroacupuncture protects intestinal barrier integrity in MAFLD mice and is associated with a macrophage α7nAChR/exosomal miR-217-5p/epithelial HO-1 signaling axis Peng Wang, Yimin Zhang, Tao He, Jiasen Sun, Xiao Wang, Jiuyang Chang, Zhijun Duan International Immunopharmacology.2026; 183: 116879. CrossRef
Cyanidin-3-glucoside mitigates zearalenone-enhanced hepatic lipotoxicity via inhibition of PXR activation Bingxin Huangfu, Teng Wang, Dongbao Cai, Jia Xu, Kunlun Huang, Zhihong Liang, Weibin Bai, Xiaoyun He Food Research International.2026; 240: 119687. CrossRef
The correlation between periodontitis and fatty liver and the improvement of NAFLD by periodontal treatment Meiying Xiang, Yusi Hua Frontiers in Oral Health.2026;[Epub] CrossRef
Exploring racial-specific associations between the food inflammation index(FII) and metabolic dysfunction-associated fatty liver disease (MAFLD) Prevalence: Data from the National Health and Nutrition Examination Survey 1999–2020 Shiyan Wang, Yu Wang, Hui Peng, Jin Wang, Enqiang Chen Medicine.2026; 105(23): e49152. CrossRef
Probiotic, synbiotic effects on the gut–liver axis: omics-enabled mechanisms and therapeutic windows Ghaleb Oriquat, Amr Ali Mohamed Abdelgawwad El-Sehrawy, Waleed K. Abdulsahib, Wael Waleed Mustafa, S. Renuka Jyothi, Priya Priyadarshini Nayak, J. Bethanney Janney, Gurjant Singh, Aashna Sinha, Farzaneh Yazdi Future Microbiology.2026; 21(8): 777. CrossRef
Evaluating performance of non-invasive tests for fibrosis detection in MASLD with Type 2 Diabetes Mellitus: Insights from VCTE-Based assessment Yusuf Kagzi, Abuzar Asif, Yanzhi Wang, Jacqueline Fischer, Sonu Dhillon Clinics and Research in Hepatology and Gastroenterology.2026; 50(7): 102879. CrossRef
Integrated Machine Learning and SHAP Analysis Identifies TRIM21 Ubiquitination of HSPA8 Driving Progression of Metabolic Dysfunction–Associated Fatty Liver Disease Liangliang Zhang, Ronglin Xu, Chao Yu, Longfei Dai, Zhen Zhang The FASEB Journal.2026;[Epub] CrossRef
Comparative discriminative ability of CVAI and traditional insulin resistance indices for MAFLD in Chinese adults with type 2 diabetes Jian Yang, Fanci Xie, Xiaoli Zhu, Hairong Zhou Frontiers in Endocrinology.2026;[Epub] CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
La phospholipase A2 associée aux lipoprotéines (Lp-PLA2) : biomarqueur pertinent et cible thérapeutique ? Dominique Bonnefont-Rousselot Annales Pharmaceutiques Françaises.2025; 83(1): 45. CrossRef
Comparing Three Ultrasound-Based Techniques for Diagnosing and Grading Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Pingping Wang, Danlei Song, JiaHao Han, Jing Zhang, Huihui Chen, Ruixia Gao, Huiming Shen, Jia Li Academic Radiology.2025; 32(4): 1949. CrossRef
The Effect of Curcumin on Glucolipid Metabolic Disorders: A Review Lifen Mo, Siyu Wan, Tekla Zékány-Nagy, Xiaoyi Luo, Xingfen Yang Food Reviews International.2025; 41(2): 543. CrossRef
Unveiling the nexus: pyroptosis and its crucial implications in liver diseases Zeyu Miao, Xiaorong Zhang, Yang Xu, Yan Liu, Qing Yang Molecular and Cellular Biochemistry.2025; 480(4): 2159. CrossRef
MASLD, MLA Pesarattu and Other Developments Anil C. Anand Journal of Clinical and Experimental Hepatology.2025; 15(1): 102465. CrossRef
Elevated concurrent carotid atherosclerosis rates in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) compared to non-alcoholic fatty liver disease (NAFLD): A cross-sectional observational study Nien-Ting Chung, Chiann-Yi Hsu, Nai-Chen Shih, Jia-Jyun Wu Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(1): 103767. CrossRef
Sex Hormone: A Potential Target at Treating Female Metabolic Dysfunction-Associated Steatotic Liver Disease? Huiyan Duan, Minmin Gong, Gang Yuan, Zhi Wang Journal of Clinical and Experimental Hepatology.2025; 15(2): 102459. CrossRef
Impact of Nonalcoholic Fatty Liver Disease on Weight Loss Outcomes After One Anastomosis Gastric Bypass Rahmatullah Athar, Masoumeh Shahsavan, Shahab Shahabi, Abdolreza Pazouki, Farah A. Husain, Mohammad Kermansaravi Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2025;[Epub] CrossRef
Trehalose Ameliorates Nonalcoholic Fatty Liver Disease by Regulating IRE1α–TFEB Signaling Pathway Shan Su, Xiaohong Liu, Min Zhu, Wen Liu, Jingyi Liu, Yujia Yuan, Fudong Fu, Zhiyong Rao, Jingping Liu, Yanrong Lu, Younan Chen Journal of Agricultural and Food Chemistry.2025; 73(1): 521. CrossRef
Deterioration of endothelial function as a risk factor for osteoporosis in patients with type 2 diabetes mellitus and MAFLD Alexander E. Berezin Acta Cardiologica.2025; 80(1): 99. CrossRef
Vitamin D supplementation alleviates high fat diet-induced metabolic associated fatty liver disease by inhibiting ferroptosis pathway Yufan Miao, Zhongyan Jiang, Hanlu Song, Yujing Zhang, Hao Chen, Wenyi Liu, Xiaonuo Wei, Longkang Li, Wenjie Li, Xing Li European Journal of Nutrition.2025;[Epub] CrossRef
Fermented rhubarb alleviates metabolic dysfunction-associated steatotic liver disease symptoms by modulating gut microbiota and activating the hepatic insulin signaling pathway Heng Yuan, Junyu Zhou, Ting Zhang, Xuangao Wu, Chen Li, Hee-Jong Yang, Do Yeon Jeong, Sunmin Park Food Bioscience.2025; 63: 105720. CrossRef
Quercetin alleviates metabolic-associated fatty liver disease by tuning hepatic lipid metabolism, oxidative stress and inflammation Ling Jiang, Rong Yi, Huan Chen, Shuwu Wu Animal Biotechnology.2025;[Epub] CrossRef
Valorizing Agro‐Food Waste for Nutraceutical Development: Sustainable Approaches for Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Related Co‐Morbidities Laura Comi, Claudia Giglione, Fationa Tolaj Klinaku, Federico Pialorsi, Valentina Tollemeto, Maria Zurlo, Antonio Seneci, Paolo Magni Food Frontiers.2025; 6(2): 670. CrossRef
Inter-organ metabolic interaction networks in non-alcoholic fatty liver disease Yu-Hong Fan, Siyao Zhang, Ye Wang, Hongni Wang, Hongliang Li, Lan Bai Frontiers in Endocrinology.2025;[Epub] CrossRef
Altered kidney function in fatty liver disease: confronting the “MAFLD-renal syndrome” Suleiman Al Ashi, Ali A. Rizvi, Manfredi Rizzo Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
Correlation between hepatic steatosis severity diagnosed by ultrasound and metabolic indexes in elderly patients with MAFLD Zhitang Liang, Renhao Huang, Lingyun Zhang Frontiers in Medicine.2025;[Epub] CrossRef
Exposure to a choline-deficient diet during pregnancy and lactation alters the liver transcriptome profile in offspring of dams with fatty liver Joanna Mikołajczyk-Stecyna, Ewelina Zuk, Agata Chmurzynska, Malgorzata Blatkiewicz, Karol Jopek, Marcin Rucinski Clinical Nutrition ESPEN.2025; 66: 9. CrossRef
miR‐18a‐5p/PXR/SREBP2 Was Involved in MAFLD Associated With Methyl Tert‐Butyl Ether Among Petrol Station Workers Hanyun Wang, Mingxiao Guo, Fengtao Cui, Mengdi Li, Xianan Zhang, Wei Gao, Xingqiang Fang, Li Chen, Ye Xin, Yucheng Sun, Piye Niu, Junxiang Ma Liver International.2025;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease and risk of nephrolithiasis: a sizeable cross-sectional study Shengqi Zheng, Tianchi Hua, Guicao Yin, Wei Zhang, Xiaoxiang Wang, Lezhong Qi, Xiayong Jing, Qibing Fan, Xiaoping Yu, Yifan Li Frontiers in Endocrinology.2025;[Epub] CrossRef
Endogenous Ethanol Production in the Human Alimentary Tract: A Literature Review Renee Stamation Journal of Gastroenterology and Hepatology.2025; 40(4): 783. CrossRef
Serum Lactate Dehydrogenase Is a Novel Predictor for the Severity in the Patients With MAFLD: A Cross-Sectional Study in Hefei, China Liang Yu, Shiming Bao, Feng Zhu, Yanyan Xu, Fuqiang Zu, Yanwei Liu, Runbeng Jiang, Song Chen, Wei Chen Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 345. CrossRef
Research progress of cysteine transporter SLC7A11 in endocrine and metabolic diseases Jiaqi Chen, Mengzhu Yuan, Jianping Wang Molecular Biology Reports.2025;[Epub] CrossRef
Obesity and Adipose-Derived Extracellular Vesicles: Implications for Metabolic Regulation and Disease Michele Malaguarnera, Omar Cauli, Andrea Cabrera-Pastor Biomolecules.2025; 15(2): 231. CrossRef
Effects of GLP-1 receptor agonist therapy on resolution of steatohepatitis in non-alcoholic fatty liver disease: a systematic review and meta-analysis Kathryn J Potter, Jackie Phinney, Tasha Kulai, Vicki Munro Journal of the Canadian Association of Gastroenterology.2025; 8(2): 47. CrossRef
IFN-γ-mediated inhibition of JAK/STAT signaling via nano-scutellarin treatment is an efficient strategy for ameliorating liver fibrosis Ting Wang, Bangguo Liu, Juan Huang, Qixin Zhao, Hongping Shen, Tao Bi, Zengjin Liu, Yong Dai, Qin Sun Journal of Translational Medicine.2025;[Epub] CrossRef
Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang European Journal of Gastroenterology & Hepatology.2025; 37(5): 652. CrossRef
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis Arun George Devasia, Adaikalavan Ramasamy, Chen Huei Leo International Journal of Molecular Sciences.2025; 26(4): 1778. CrossRef
Psychosocial risks in metabolic dysfunction-associated steatotic liver disease Hanne Åström, Christine Takami Lageborn, Hannes Hagström Expert Review of Gastroenterology & Hepatology.2025; 19(3): 273. CrossRef
Metabolic dysfunction-associated steatotic liver disease in adults Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba Nature Reviews Disease Primers.2025;[Epub] CrossRef
A Comprehensive Review of Metabolic Dysfunction-Associated Steatotic Liver Disease: Its Mechanistic Development Focusing on Methylglyoxal and Counterbalancing Treatment Strategies Izabela Berdowska, Małgorzata Matusiewicz, Izabela Fecka International Journal of Molecular Sciences.2025; 26(6): 2394. CrossRef
A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease Michelle Thuy Nguyen, Andrew Lian, Frederick Timothy Guilford, Vishwanath Venketaraman Biomedicines.2025; 13(3): 644. CrossRef
Red Meat Amino Acids for Beginners: A Narrative Review Benjamin Barr, Danielle Levitt, Lauren Gollahon Nutrients.2025; 17(6): 939. CrossRef
Clinical Insights into Non-Alcoholic Fatty Liver Disease and the Therapeutic Potential of Flavonoids: An Update Aleksandra Kozłowska Nutrients.2025; 17(6): 956. CrossRef
Estimated sdLDL-C as a biomarker of hepatic steatosis severity in MASLD: a retrospective study Shuo Jiang, Fan Zhang, Hui Yang, Xue Han, Jieru Mao, Guojun Zheng, Yan Fan BMC Gastroenterology.2025;[Epub] CrossRef
Fu brick tea supplementation ameliorates non-alcoholic fatty liver disease and associated endotoxemia via maintaining intestinal homeostasis and remodeling hepatic immune microenvironment Gaolong Zuo, Menghua Li, Xiaoli Guo, Ling Wang, Yanyan Yao, Jian-an Huang, Zhonghua Liu, Yong Lin Food Research International.2025; 209: 116207. CrossRef
Association of occupational physical activity and sedentary behaviour with the risk of hepatocellular carcinoma: a case-control study based on the Inpatient Clinico-Occupational Database of Rosai Hospital Group Shoko Nakazawa, Kota Fukai, Kei Sano, Yuko Furuya, Keika Hoshi, Noriko Kojimahara, Akihiro Toyota, Masaaki Korenaga, Masayuki Tatemichi BMJ Open.2025; 15(3): e092020. CrossRef
Impact of blood lead and manganese levels on metabolic dysfunction-associated steatotic liver disease prevalence: insights from NHANES (2017–2020) Wenying Guo, Ting Weng, Yufei Song BMC Gastroenterology.2025;[Epub] CrossRef
Does the hepatologist still need to rely on aminotransferases in clinical practice? A reappraisal of the role of a classic biomarker in the diagnosis and clinical management of chronic liver diseases Patrizia Burra, Calogero Cammà, Pietro Invernizzi, Fabio Marra, Maurizio Pompili Annals of Hepatology.2025; 30(1): 101900. CrossRef
Omega-3 Fatty Acids, Furan Fatty Acids, and Hydroxy Fatty Acid Esters: Dietary Bioactive Lipids with Potential Benefits for MAFLD and Liver Health Camil Merheb, Sabine Gerbal-Chaloin, François Casas, Mona Diab-Assaf, Martine Daujat-Chavanieu, Christine Feillet-Coudray Nutrients.2025; 17(6): 1031. CrossRef
Photon-counting CT–derived Quantification of Hepatic Fat Fraction: A Clinical Validation Study Tatjana Dell, Narine Mesropyan, Yannik Layer, Verena Tischler, Leonie Weinhold, Johannes Chang, Christian Jansen, Bernhard Schmidt, Markus Jürgens, Alexander Isaak, Patrick Kupczyk, Claus Christian Pieper, Carsten Meyer, Julian Luetkens, Daniel Kuetting Radiology.2025;[Epub] CrossRef
Unravelling the Role of PANoptosis in Liver Diseases: Mechanisms and Therapeutic Implications Wanyuan Xiong, Junfeng Li, Aiping Tian, Xiaorong Mao Liver International.2025;[Epub] CrossRef
Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020 Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu Frontiers in Physiology.2025;[Epub] CrossRef
Metrology for MRI: the field you’ve never heard of Matt G. Hall, Matt Cashmore, Hyo-Min Cho, Bernd Ittermann, Kathryn E. Keenan, Christoph Kolbitsch, Changwoo Lee, Chengwei Li, Asante Ntata, Katie Obee, Zhang Pu, Stephen E. Russek, Karl F. Stupic, Lukas Winter, Luca Zilberti, Michael Steckner Magnetic Resonance Materials in Physics, Biology and Medicine.2025; 38(3): 387. CrossRef
Dual inhibition of hepatic ACLY and ACSS2: A synergistic approach to combat NAFLD through lipogenesis reduction and mitochondrial enhancement Mengdi Zhang, Jinliang Ji, Yuanyuan Lei, Fujian Qin, Yitong Tao, Ning Li, Jinlei Bian, Zhiyu Li, Maode Lai, Zhixia Qiu Pharmacological Research.2025; 215: 107706. CrossRef
MASLD or MAFLD: fatty liver by any name will pose the same challenge Anil Chandra Anand, Dibyalochan Praharaj Metabolism and Target Organ Damage.2025;[Epub] CrossRef
Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways Setareh Satari, Inês N. R. Mota, Ana Carolina Leão Silva, Haissa Oliveira Brito, Paula A. Oliveira, Rui Miguel Gil da Costa, Rui Medeiros International Journal of Molecular Sciences.2025; 26(9): 3952. CrossRef
Relationship of serum 25(OH)D3 and PTX3 with liver fat content in patients with non-alcoholic fatty liver disease: Diagnostic value for liver fibrosis Jian-Ji Dai, Yi Deng, Guo-Feng Wang, Kai-Qin Lin, Jian-Rong He, Xiao-Gang Hu World Chinese Journal of Digestology.2025; 33(3): 192. CrossRef
Role of regulatory T cells in inflammatory liver diseases Linjie Yang, Song Guo Zheng Autoimmunity Reviews.2025; 24(6): 103806. CrossRef
Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis Qihua Duan, Ruixiang Hu, Yan Chen, Henry Wade, Szczepan Kaluzny, Bingrui Zhang, Rongxue Wu, Guangnan Liu, Cunchuan Wang, Edward N. Harris, Qiaozhu Su Genes & Diseases.2025; 12(6): 101648. CrossRef
Association of serum iron status with MASLD and liver fibrosis Wenying Guo, Ting Weng, Yufei Song, Anna Di Sessa PLOS ONE.2025; 20(4): e0319057. CrossRef
Nephrological, Pulmonary, and Dermatological Complications in the Context of MAFLD/NAFLD: A Narrative Review Vlad Pădureanu, Dalia Dop, Lucrețiu Radu, Dumitru Rădulescu, Rodica Pădureanu, Denisa Floriana Vasilica Pîrșcoveanu, Daniel Cosmin Caragea Metabolites.2025; 15(4): 272. CrossRef
Rhizoma Atractylodis Macrocephalae reduces HFD-induced NAFLD in mice through activated AMPK mediated inhibition of fatty acid synthesis Ke Zheng, RuiShuo Zhang, Yijing Xin, Yuge Zhou, Jiacheng Lin, Weifan Huang, Fang Wang, Liu Yang, Xuehua Sun, Xiaoni Kong Liver Research.2025;[Epub] CrossRef
Increased Mechanical Index Improves Shear Wave Elastography: Pilot Study of Signal Enhancement Scott Schoen, Michael Wang, Sunethra Dayavansha, Kim Naja, Viksit Kumar, Rimon Tadross, Kathleen Pope, Lauren Ling, David Hunt, Mary K. Peters, Ann Iafrate, Nathaniel D. Mercaldo, Kurt Sandstrom, TaeYun Kim, Mike Washburn, Theodore T. Pierce, Anthony E. S Ultrasound in Medicine & Biology.2025; 51(7): 1070. CrossRef
A Systematic Review of the Beneficial Effects of Berry Extracts on Non-Alcoholic Fatty Liver Disease in Animal Models Alejandro García-Beltrán, Aida Lozano Melero, Rosario Martínez Martínez, Jesús María Porres Foulquie, María López Jurado Romero de la Cruz, Garyfallia Kapravelou Nutrition Reviews.2025; 83(5): 819. CrossRef
Linghe granules reduces hepatic lipid accumulation in Non-alcoholic fatty liver disease through regulating lipid metabolism and redox balance Yuting Hu, Ni'ao Li, Rumian Zhang, Jia Wang, Dongdong Fang, Qianmei Zhou, Hua Zhang, Hong Cai, Yiyu Lu Phytomedicine.2025; 141: 156654. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies Parag Jain, Akanksha Jain, Rohitas Deshmukh, Pradeep Samal, Trilochan Satapathy, Ajazuddin Clinics and Research in Hepatology and Gastroenterology.2025; 49(6): 102584. CrossRef
Luteolin Relieves Metabolic Dysfunction-Associated Fatty Liver Disease Caused by a High-Fat Diet in Rats Through Modulating the AdipoR1/AMPK/PPARγ Signaling Pathway Pongsakorn Taweesap, Prapassorn Potue, Juthamas Khamseekaew, Metee Iampanichakul, Banyaphon Jan-O, Poungrat Pakdeechote, Putcharawipa Maneesai International Journal of Molecular Sciences.2025; 26(8): 3804. CrossRef
Association between non-skimmed milk consumption and metabolic dysfunction-associated fatty liver disease in US adults: insights from NHANES data Futao Wu, Fuying Zheng, Xue Li, Danzhu Wu, Honghao Li, Yingyi Zeng, Yan Tang, Side Liu, Aimin Li BMC Gastroenterology.2025;[Epub] CrossRef
Discovery of the first-in-class FABP/PPAR multiple modulator for the treatment of metabolic dysfunction-associated steatohepatitis Ya Chen, Zibin Liao, Jianming Mao, Wenxin Wang, Yuxia Liu, Wei Dai, Zheng Wen, Sishi Liu, Yayi Chen, Yiming Ma, Xiaoying Wang, Zheng Li European Journal of Medicinal Chemistry.2025; 291: 117635. CrossRef
Astragaloside IV as a promising therapeutic agent for liver diseases: current landscape and future perspectives Chunyan Chen, Xiaolan Bu, Liping Deng, Jiayan Xia, Xinming Wang, Li Chen, Wen Li, Jie Huang, Qixiang Chen, Cheng Wang Frontiers in Pharmacology.2025;[Epub] CrossRef
Targeting Metabolism: Innovative Therapies for MASLD Unveiled Weixin Wang, Xin Gao, Wentong Niu, Jinping Yin, Kan He International Journal of Molecular Sciences.2025; 26(9): 4077. CrossRef
Unsupervised Test-Time Adaptation for Hepatic Steatosis Grading Using Ultrasound B-Mode Images Pedro Vianna, Paria Mehrbod, Muawiz Chaudhary, Michael Eickenberg, Guy Wolf, Eugene Belilovsky, An Tang, Guy Cloutier IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.2025; 72(5): 601. CrossRef
Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry and Network Pharmacology Reveal the Mechanisms of Rhodiola crenulata in Improving Non-Alcoholic Fatty Liver Disease Xin Zeng, Jianwei Wang, Qinyi Xu, Chengdan Deng, Xi Yi, Shang Wang, Ling Yao, Wei Xiang Current Issues in Molecular Biology.2025; 47(5): 324. CrossRef
Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease Hidenori Kido, Eishiro Mizukoshi, Masahiro Yanagi, Li Shihui, Takuya Seike, Hidetoshi Nakagawa, Tetsumori Yamashima, Yoshitake Shiraishi, Noriyuki Ozaki, Kenichi Harada, Hikari Okada, Hisanori Goto, Kumi Kimura, Yasuhiko Yamamoto, Taro Yamashita Journal of Gastroenterology.2025; 60(8): 990. CrossRef
Modulation of liver lipid metabolic pathways by central nervous system ER stress Han Rae Kim, Parisa Tabiatnejad, Hovhannes Arestakesyan, Colin N. Young American Journal of Physiology-Endocrinology and Metabolism.2025; 328(6): E833. CrossRef
Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia Marina Ribas Losasso, Maria Luiza Cesto Parussolo, Antony Oliveira Silva, Rosa Direito, Karina Quesada, Claudia Rucco Penteado Detregiachi, Marcelo Dib Bechara, Nahum Méndez-Sánchez, Ludovico Abenavoli, Adriano Cressoni Araújo, Ricardo de Alvares Goulart, International Journal of Molecular Sciences.2025; 26(10): 4673. CrossRef
Unveiling the role of IL7R in metabolism-associated fatty liver disease leading to hepatocellular carcinoma through transcriptomic and machine learning approaches Priyadharshini Annadurai, Arnold Emerson Isaac Discover Oncology.2025;[Epub] CrossRef
Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease) Alexander A. Baranov, Galina V. Volynets, Nikolay N. Vlasov, Larisa G. Goryacheva, Margarita M. Gurova, Vera A. Greshnyakova, Anna N. Zaviyalova, Nina V. Evdokimova, Marina Yu. Komissarova, Leyla S. Namazova-Baranova, Valeriya P. Novikova, Elena V. Pavlov Pediatric pharmacology.2025; 22(2): 147. CrossRef
Association between organochlorine pesticides and metabolic dysfunction-associated steatotic liver disease: Findings from the Dongfeng-Tongji cohort Yi Guo, Xin Guan, Yutong You, Chengyong Jia, Yuhui Lin, Zhen Yin, Yu Yin, Guorong Zhong, Yuying Wen, Wenhui Li, Hui Zhao, Shengli Chen, Xi Wang, Xinlian Li, Xuanwen Mu, Pinpin Long, Hao Wang, Xiaomin Zhang, Meian He, Yu Yuan, Tao Jing, Huan Guo, Tangchun Environment International.2025; 201: 109571. CrossRef
KRT23 as a Potential Target for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): Evidence From Bioinformatics Analysis, Human Gene Polymorphism and Animal Experiments Yangmin Hao, Tao Zhang, Shaliyan Tuerxunmaimaiti, Ye Tian, Xinyu Wang, Zhiming Li, Liang Zhao, Lei Bai, Qu Chen, Cheng Li, Ayiguzhali Abulitipu, Rui Wang, Sheng Jiang, Guoli Du International Journal of General Medicine.2025; Volume 18: 2807. CrossRef
Evolving Public Attention to Steatotic Liver Disease: A 20‐Year Analysis (2004–2024) Pojsakorn Danpanichkul, Charat Thongprayoon, Kanokphong Suparan, Donghee Kim, Ornpailin Wanichthanaolan, Phuuwadith Wattanachayakul, Yanfang Pang, Mark D. Muthiah, Anand V. Kulkarni, Ju Dong Yang, Apichat Kaewdech, Wisit Cheungpasitporn, Karn Wijarnpreech Journal of Gastroenterology and Hepatology.2025; 40(8): 2053. CrossRef
ECM formation and degradation during fibrosis, repair, and regeneration Alejandro E. Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, Joachim Høg Mortensen, Signe Holm Nielsen, Quentin M. Anstee, Arun J. Sanyal, Morten A. Karsdal, Detlef Schuppan npj Metabolic Health and Disease.2025;[Epub] CrossRef
The role of SIRT2 in homeostatic medicine and aging intervention Yue Li, Longchuan Han, Yinkun Fu, Yingting Zhang, Zhihui Zou, Jing Luo, Xinxin Tang, Lihong Tian, Yuheng Lu, Ying Huang, Ming He Oral Science and Homeostatic Medicine.2025; 1(1): 9610009. CrossRef
Integration of Metabolomics, Lipidomics, and Machine Learning for Developing a Biomarker Panel to Distinguish the Severity of Metabolic‐Associated Fatty Liver Disease Yanqiao Hui, Jiameng Qu, Junjie Yang, Hanwen Zhang, Chen Liang, Naixin Miao, Qian Zhang, Huarong Xu, Yiling Li, Qing Li Biomedical Chromatography.2025;[Epub] CrossRef
Prevalence and predictors of non‐alcoholic fatty liver disease (NAFLD) and metabolic dysfunction‐associated fatty liver disease (MAFLD) in Indian women with polycystic ovarian syndrome Aditi Rathi, Deepti Goswami, Anju Garg, Smita Kaushik, Niharika Dhiman Journal of Obstetrics and Gynaecology Research.2025;[Epub] CrossRef
The role of plasma glucose in association of food-specific serum immunoglobulin G reactivity with metabolic dysfunction-associated fatty liver disease: a real-world cross-sectional study Guanchao Sun, Wenjuan Wu, Binbin Su, Ru Zhang, Xiaoyu Dong, Lihui Wang, Shiping Xu, Hui Shi Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Medical Implications of Renaming Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Yu-Jin Choi, Chang-Gue Son Journal of Korean Medicine.2025; 46(2): 40. CrossRef
The FMO3/TMAO/HSP90β axis aggravates MAFLD by disrupting mitochondrial protein homeostasis Jin Guo, Yukun Wang, Danmei Zhang, Chunxia Shi, Xiaoya Zhang, Xun Li, Zuojiong Gong Cellular Signalling.2025; 134: 111960. CrossRef
Anti-steatotic effect of Opuntia ficus-indica extracts rich in betalains and phenolics from fruit peel and pulp of different varieties in in vitro models Irene Besné-Eseverri, Jenifer Trepiana, Itziar Eseberri, Andrea Gómez-Maqueo, M. Pilar Cano, Joao Tomé-Carneiro, Alberto Dávalos, María P. Portillo Journal of Physiology and Biochemistry.2025; 81(4): 1305. CrossRef
Regulatory Mechanisms of Phenolic Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review Shengyu Zhang, Congcong Shen, Han Di, Yanhong Wang, Feng Guan Antioxidants.2025; 14(7): 760. CrossRef
Fatty liver index and risk of type 2 diabetes of adults with normoglycemia: Insights into insulin sensitivity and beta-cell function Ji Hyun Bae, Min Jin Lee, Su Hyun Kim, Joo Yeon Kim, Ah Reum Khang, Yang Ho Kang, Dongwon Yi, Guoying Wang PLOS One.2025; 20(6): e0327058. CrossRef
Loss of endothelial ZEB2 in mice attenuates steatosis early during metabolic dysfunction-associated steatotic liver disease Wouter Dheedene, Stefaan Verhulst, Louise Demuynck, Bram Callewaert, Willeke de Haan, Stefan Vinckier, Jore Van Wauwe, Petra Vandervoort, Marleen Lox, Mathias Stroobants, Renaud Lavend’homme, Wilfred F. J. van IJcken, Elizabeth A. V. Jones, An Zwijsen, Ma Scientific Reports.2025;[Epub] CrossRef
Prevalence of advanced liver fibrosis in the general population of the Paris region according to FIB-4 score and liver risk score Henri Tran, Stefano Caruso, Anne-Laure Mazialivoua, Cecile Fargeat, Odile Rousselet, Adrien Ko, Vincent Leroy, Patrick Ingiliz BMC Gastroenterology.2025;[Epub] CrossRef
TyG-BMI as a superior predictor of MAFLD and pre-MAFLD in Chinese adults: a cross-sectional study Xinru Huang, Yanyun Hu, Lining Dong, Liying Zhu, Jie Li, Ji Hu, Wei Shao, Yongde Peng, Fang Liu BMC Gastroenterology.2025;[Epub] CrossRef
Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD Zhonghao Jiang, Baolin Qian, Tongjie Xu, Junjie Bai, Wenguang Fu ImmunoTargets and Therapy.2025; Volume 14: 719. CrossRef
The expanding role of semaglutide: beyond glycemic control Malek Zarei, Masoumeh Sabetkasaei, Masoud Mozafari, Sasan Zaeri Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Quantitative characterization of drug metabolism and transport alterations in obesity with metabolic fatty liver disease: A physiologically based pharmacokinetic modelling approach Yuewu Xie, Xiaoqin Bai, Chaozhuang Shen, Chaoran Xu, Chi Cui, Yujie Yang Journal of Pharmaceutical Sciences.2025; 114(9): 103906. CrossRef
Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV Hui Wang, Yunqin Jiang, Shiyun Wang, Chanchan Lu, Lumin Tang, Tingting Gu, Shi Shu Acta Pharmaceutica.2025; 75(3): 309. CrossRef
Differential effects of sleep duration on cardiovascular risk in metabolic-associated fatty liver disease vs. without metabolic-associated fatty liver disease: evidence from National Health and Nutrition Examination Survey and Mendelian randomization Siyao Wang, Xinyi Liu, Jia He, Yihan Cui, Ai Jia European Journal of Gastroenterology & Hepatology.2025; 37(12): 1380. CrossRef
Lipid Hormones at the Intersection of Metabolic Imbalances and Endocrine Disorders Maria-Zinaida Dobre, Bogdana Virgolici, Ruxandra Cioarcă-Nedelcu Current Issues in Molecular Biology.2025; 47(7): 565. CrossRef
Shift in the urinary metabolome associated with 2,3,7,8-tetrachlorodibenzo-p-dioxin activation of the hepatic aryl hydrocarbon receptor Warren J. Sink, Russell Fling, Ali Yilmaz, Rance Nault, Delanie Goniwiecha, Jack R. Harkema, Stewart F. Graham, Tim Zacharewski Scientific Reports.2025;[Epub] CrossRef
Serum metabolites and gut microbiota mediate the causal link between anxiety and nonalcoholic fatty liver disease: a Mendelian randomization analysis Siyao Wang, Xinyi Liu, Jia He, Yihan Cui, Ai Jia European Journal of Gastroenterology & Hepatology.2025; 37(12): 1370. CrossRef
Applications of artificial intelligence in liver cancer: A scoping review Andrea Chierici, Fabien Lareyre, Antonio Iannelli, Benjamin Salucki, Sébastien Goffart, Lisa Guzzi, Elise Poggi, Hervé Delingette, Juliette Raffort Artificial Intelligence in Medicine.2025; 169: 103244. CrossRef
Soybean genistin-driven gut microbiota-derived butyrate synthesis activates the SIRT1 signaling pathway to ameliorate metabolic fatty liver Guohui Yi, Wanying Sun, Xueer Zhang, Zhongtao Wang, Xiaodan Yu, Canyang Zhu, Kaiwen Lin Free Radical Biology and Medicine.2025; 239: 336. CrossRef
Relación entre el control de la psoriasis y la enfermedad hepática esteatósica asociada a disfunción metabólica Citlalli Guadalupe Hernández Guzmán, Blanca Elena Verazaluce Rodríguez, Lauro Fabián Amador Medina, Graciela López Mata, Erick Josefat Díaz Huerta, Óscar Noel Chávez Hernández Piel.2025; 40(9): 558. CrossRef
MASLD vs. MAFLD. A narrative review Amedeo Lonardo, Ming-Hua Zheng, Mohammed Eslam Exploration of Digestive Diseases.2025;[Epub] CrossRef
Sweroside: unveiling broad therapeutic potential—from mechanistic insights to clinical potential Liu Peng, Man Zuo, Tian Qiu, Wenying Lan, Yue Wen, Xiao-Qin Ye Frontiers in Pharmacology.2025;[Epub] CrossRef
Mechanisms and Therapeutic Advances of PXR in Metabolic Diseases and Cancer Yuanbo Bi, Sifan Liu, Lei Wang, Daiyin Peng, Weidong Chen, Yue Zhang, Yanyan Wang International Journal of Molecular Sciences.2025; 26(16): 8029. CrossRef
Understanding MASLD — from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist Carlo Ratti, Mattia Malaguti, D'Aniello Emanuele, Antonio Bellasi, Gianluca Sanna Atherosclerosis.2025; 409: 120495. CrossRef
Global burden of NAFLD 1990–2021 and projections to 2035: Results from the Global Burden of Disease study 2021 Yuqin Mao, Jiqing Du, Baoguo Li, Jiong Wang, Shaoyan Xuan, Shu Yang, Zhihua Tang, Minxiu Wang, Hamidreza Karimi-Sari, PLOS One.2025; 20(8): e0330504. CrossRef
Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study Jungha Park, Jin-Wook Kim, Soo Lim Annals of Nutrition and Metabolism.2025; : 1. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review Marcelo do Rego Maciel Souto Maior, Nathália de Lacerda Interaminense Ribeiro, Hannah Vicentini Vitoriano Silva, Edmundo Pessoa Lopes, Emilia Chagas Costa Biomedicines.2025; 13(9): 2162. CrossRef
Association of Daily Steps with Incident Nonalcoholic Fatty Liver Disease: Evidence from the UK Biobank Cohort EVELYNNE S. FULDA, LAURA PORTAS, CHARLIE HARPER, DAVID PREISS, DERRICK BENNETT, AIDEN DOHERTY Medicine & Science in Sports & Exercise.2025; 57(9): 1905. CrossRef
Performance Assessment of ChatGPT-4.0 and ChatGLM Series in Traditional Chinese Medicine for Metabolic Associated Fatty Liver Disease: Comparative Study Xionghui Wang, Tianxiao Zheng, Bo Liu, Zhi Pei, Kaihan Meng, Changquan Ling JMIR Formative Research.2025; 9: e66503. CrossRef
Circulating ORM2 as a Biomarker of Metabolic Dysfunction: Evidence from the KADEM Study in Kuwaiti Adults Mohamed Abu-Farha, Ahmed N. Albatineh, Bader Alawadh, Loulwa Alsalem, Irina Al-Khairi, Preethi Cherian, Fahad Al-Ajmi, Mohammad Qaddoumi, Muhammad Abdul-Ghani, Fahd Al-Mulla, Jehad Abubaker International Journal of Molecular Sciences.2025; 26(17): 8326. CrossRef
Hic-5 deficiency attenuates MAFLD by inhibiting neutrophils migration via the CXCL1-CXCR2 axis Bingyu Ren, Han Li, Shenglu Liu, Zhiwei Huang, Junjie Bai, Zhonghao Jiang, Tongjie Xu, Boyuan Gu, Wenhao Yu, Lei Sun, Peng Tan, Wenguang Fu Journal of Gastroenterology.2025; 60(12): 1535. CrossRef
Association of exposure to phenols, pesticides, and phthalates with hepatic steatosis and MASLD in adolescents: the potential role of inflammation and lifestyle factors Xiaodie Yao, Cai Tang, Yu Li, Congwei You, Haoyang Zhang, Xiaohong Gu, Kerong Liu, Le Zhang Metabolism and Target Organ Damage.2025;[Epub] CrossRef
A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models Marialuisa de Ceglia, Rubén Tovar, Miguel Rodríguez-Pozo, Antonio Vargas, Ana Gavito, Juan Suárez, Elena Baixeras, Fernando Rodríguez de Fonseca, Juan Decara Biochemical Pharmacology.2025; 242: 117364. CrossRef
Association of elevated Alpha-1-Acid glycoprotein with MAFLD prevalence in young and middle-aged women: a cross-sectional study based on NHANES 2017–2020 Yi Xiao, Xian Luo, Yinghao Fu, Haijuan Huang, Qiaoping Gao, Jiansong Liu, Daxin Pang, Xiaolu Liang, Huadi Chen, Hao Xu Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Development of a nomogram model for predicting coronary heart disease in patients with metabolic-associated fatty liver disease Zhengliang Li, Xiaokai Chen, Juan Wang, Weirui Chen, Run Zhang, Lihua Cao, Shaoting Shi, Linlin Ren, Wenzhong Zhang Frontiers in Cardiovascular Medicine.2025;[Epub] CrossRef
In Silico Study of Natural Polyphenols as Potential Metabolic Modulators in Mitigating Lipotoxicity in Non-Alcoholic Fatty Liver Disease via Thyroid Hormone Receptor Alpha Activation Evangelia K. Konstantinou, Athanasios A. Panagiotopoulos, Maria Dimitriou Current Issues in Molecular Biology.2025; 47(9): 777. CrossRef
A Comprehensive Systematic Review on Therapeutic Discovery of NAFLD Drugs Sajja Keerthi Vathsalya, A. Gnanavel, N. Hima Bindu, S. Saravana Kumar, B. Naveen Kumar Research Journal of Pharmacy and Technology.2025; : 4564. CrossRef
Sugar-sweetened beverage consumption predicts metabolic associated fatty liver disease in patients with type 2 diabetes mellitus Zhenjun Yu, Mengdie Chen, Shicheng Gu, Chaohui Wang, Ping Feng, Gang Lin Frontiers in Endocrinology.2025;[Epub] CrossRef
Analysis of the Association Between TG/HDL, TyG, TyG-BMI, and ZJU Indices with Metabolic Dysfunction-Associated Fatty Liver Disease in Patients with Type 2 Diabetes Yunyi Yang, Hongping Wang, Yanming He, Xiaoli He, Zheng Yao, Hongjie Yang Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 3797. CrossRef
Analysis of subgingival microbial community structure in MAFLD patients with periodontitis Hai He, Jingli Zhu, Chuyi Li, Qisheng Shen, Jiarui Cao, Jinhai Ma, Zhenghu Feng, Zhiqiang Li, Tianzhu Song Clinical Oral Investigations.2025;[Epub] CrossRef
Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes Asiyeh Masaeli, Mohammad Taghi Goodarzi, Adel Mohammadalipour, Safa Ali-Asgari, Mohammad Reza Mirzaei, Mohsen Hani Scientific Reports.2025;[Epub] CrossRef
Nonlinear association between TyG-BMI and MAFLD: A cross-sectional study Qiuping Wang, Yuan Su, Jing Niu, Yan Wang, Liping Liu, Yanhong Hao, Qian Wu PLOS One.2025; 20(10): e0331140. CrossRef
Polycystic ovarian syndrome a risk factor for non-communicable diseases: insights into recent research and prevention approaches Iqra Naeem, Ayman Zehra, Faiza Rehman, Abid Hussain, Azhar Hussain, Nisar Hussain, Muhammad Waseem, Reem Mohammed Alqahtani, Ghalia Shamlan, Isam A. Mohamed Ahmed, Muhammad Faisal Manzoor, Muhammed Adem Abdullahi Journal of Ovarian Research.2025;[Epub] CrossRef
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management Carlo Acierno, Riccardo Nevola, Fannia Barletta, Katarzyna Zielińska, Luca Rinaldi, Ferdinando Carlo Sasso, Caterina Conte, Luigi Elio Adinolfi, Alfredo Caturano Exploration of Medicine.2025;[Epub] CrossRef
Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu Frontiers in Nutrition.2025;[Epub] CrossRef
Perilipins: key targets for regulating lipid metabolism and alleviating abnormal lipid metabolism through exercise Yan-Jun Niu, Jing-Jing Liu, Jing-Hua Zhang, Shi-Qi Lu, Ke Wang, Zheng Zhu, Zhen-Bo Cao Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
CircRNA in Digestive Diseases: Recent Advances in Fundamental Mechanism and Clinical Potential Yuanye Ji, Shun Zhang, Ting Cai, Liyun Fu, Qinzhi Deng, Peng Zhu Current Molecular Medicine.2025; 25(9): 1107. CrossRef
Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis Marion Pradeau, Sandrine Beaulieu, Véronique Paquet, Jocelyn Trottier, Mélanie Verreault, Stéphanie Ferland, Olivier Barbier, Anne-Marie Carreau American Journal of Physiology-Endocrinology and Metabolism.2025; 329(5): E644. CrossRef
Analysis of risk factors associated with metabolic-associated fatty liver disease from Suzhong Region, China: a cross-sectional study Shuai Zhang, Hao Liang, Jun Liu, Ye Zhu BMJ Open.2025; 15(10): e096598. CrossRef
Predicting Metabolic Dysfunction–Associated Fatty Liver Disease Phenotypes Among Adults: 2-Stage Contrastive Learning Method Sizhe Jasmine Chen, Da Xu, Derek K Hu, Paul Jen-Hwa Hu, Ting-Shuo Huang JMIR Medical Informatics.2025; 13: e75747. CrossRef
Explainable machine learning model for classifying atherosclerotic cardiovascular disease in patients with metabolic dysfunction-associated steatotic liver disease Zhengliang Li, Xiaokai Chen, Linlin Ren, Banghui Wang, Shimiao Ruan, Juan Wang, Wenzhong Zhang Frontiers in Endocrinology.2025;[Epub] CrossRef
PGC-1α regulates lipid accumulation by coordinating fatty acid synthesis and oxidation in goose fatty liver Jiahui Li, Mengqing Lv, Long Liu, Tuoyu Geng, Daoqing Gong, Minmeng Zhao Poultry Science.2025; 104(12): 106052. CrossRef
Association of vitamin D levels with metabolic dysfunction-associated fatty liver disease in children aged 12–18 years Xuejie Gao, Yuyun Chen, Xinrui Wang, Yuehang Chen, Xiaoyan Chen, Haibo Li, Hong Ye Frontiers in Nutrition.2025;[Epub] CrossRef
Bifidobacterium bifidum enhances hepatic mitochondrial β-oxidation and ameliorates MAFLD in a high-fat diet rat model Fatemeh Dashti, Ava Bolandparvaz, Anahita Panji, Zahra Hojatifar, Mahdi Alinejad, Mahtab Mehboodi, Mohammad Hassan Maleki, Afsaneh Mirshekari, Elham Nadimi Scientific Reports.2025;[Epub] CrossRef
Betulinic acid as a novel AT1R inhibitor: attenuation of liver fibrosis via modulation of endothelial–mesenchymal transition in chronic hepatic injury Bingwen Zhu, Xiyu Dai, Chunyan Liu, Tao Bi, Shenglu Liu, Lei Chen, Ting Wang, Qixin Zhao, Xinyue Liu, Qin Sun, Yingcheng Yang, Zengjin Liu Journal of Translational Medicine.2025;[Epub] CrossRef
Qushi Huayu decoction alleviates NAFLD in mice by regulating gut microbiota homeostasis in the gut-liver axis via the pregnane X receptor Yuan Xu, Yiming Ni, Mingmei Zhou, Xiaojun Gou European Journal of Pharmacology.2025; 1008: 178366. CrossRef
Serum Extracellular Vesicles as Pathogenetic Signals in Obese and Lean Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Chi-Yi Chen, Che-Yu Hsu, Wei-Pang Chung, Hung-Yu Sun, Tzu-Ching Kao, Tzu-Yi Chen, Xing-Min Li, Wei-Lung Huang, Kung-Chia Young Metabolites.2025; 15(11): 746. CrossRef
Harnessing serum VOCs and machine learning for the early detection of MAFLD Xin Li, Xiaoyue Zhao, Ruonan Zhang, Xuewei Zhuang Frontiers in Endocrinology.2025;[Epub] CrossRef
Diabetes mellitus and liver: Non-obvious aspects A. O. Bueverov, E. L. Bueverova FOCUS. Endocrinology.2025; 6(3): 41. CrossRef
The role of hepatic steatosis Index, fatty liver Index, and metabolic and hormonal biomarkers in differentiating MASLD in polycystic ovary syndrome Enes Ucgul, Burak Menekse, Huseyin Demirci, Erman Cakal Journal of Endocrinological Investigation.2025; 49(4): 901. CrossRef
К эпидемиологии жировой болезни печени, связанной с метаболической дисфункцией (систематический обзор литературы)
Вера Людвиговна Грицинская, Валерия Павловна Новикова Children's medicine of the North-West.2025; 13(3): 108. CrossRef
Associations between composite systemic inflammation indicators(CAR, CLR, SII, AISI, SIRI, and CALLY) and metabolic dysfunction-associated fatty liver disease (MAFLD): evidence from a two-stage study in China Jing Zhao, Quan Zhou, Yun Wang, Fangfei Xie, Jingyi Fan Frontiers in Immunology.2025;[Epub] CrossRef
Betaine Attenuates High‐Fat‐Diet‐Induced Metabolism‐Associated Steatotic Liver Disease via the Inhibition of Ferroptosis Through the Nrf2/GPX4 Axis Xiao‐jun Zhai, Cheng Xiao, Chun‐ru Yang, Ze‐rui Ding, Dong‐mei Wang, Jie‐ying Liu, Yu Miao The FASEB Journal.2025;[Epub] CrossRef
Regulatory Role of Nuclear Factor of Activated T Cells c4 in the Development of Metabolic dysfunction-associated Fatty Liver Disease Tong Shen, Jia Chen, Luyao Li, Guohao Li, Qianyu Guo, Meie Liang, Quanhai Pang Current Atherosclerosis Reports.2025;[Epub] CrossRef
MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action Thong Duy Vo, Huong Tu Lam Frontiers in Clinical Diabetes and Healthcare.2025;[Epub] CrossRef
Lactobacillus gasseri TF08-1 ameliorates high-fat diet induced nonalcoholic fatty liver disease and regulates gut microbiota in mice Qianyue Xu, Ningning He, Yu Tian, Zhinan Wu, Haoyu Wang, Bei Liu, Zizhen Yang, Haifeng Zhang, Qiang Luo, Yiyi Zhong, Liang Xiao, Shangyong Li, Yuanqiang Zou Journal of Applied Microbiology.2025;[Epub] CrossRef
Traditional Chinese medicine for non-alcoholic fatty liver disease: an overview of systematic reviews with evidence mapping and metabolic outcome assessment Juanjuan Li, Ruimin Jiao, Wenquan Su, Wei Chen, Xiangyu Hu, Shuai Xu, Lie Xu, Weiwei Yao, Kejia Liu, Hong You, Jingjie Zhao Frontiers in Pharmacology.2025;[Epub] CrossRef
Impact of Polyphenol Supplementation on Energy Expenditure Measured by Indirect Calorimetry in Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Pilot Randomized Study Christine Haïkal, Marie-Catherine Turcotte, Véronique Bélanger, Sophia Morel, Anik Cloutier, Emile Levy, Valérie Marcil, Ramy El-Jalbout, Véronique Groleau Healthcare.2025; 13(24): 3215. CrossRef
Research Progress on the Role and Mechanism of Flavonoids in Improving Metabolic Associated Fatty Liver Disease Lala Qin, Qingsong Xiao, Xin Deng Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 4597. CrossRef
STEATOTIC LIVER DISEASE: THE IMPACT OF TEA AND COFFEE CONSUMPTION. LITERATURE REVIEW
V.S. Rakhmetova Наука и здравоохранение.2025; (5(27)): 261. CrossRef
Dual roles of T cells in metabolic dysfunction–associated steatohepatitis pathogenesis and liver fibrosis: From inflammation to therapeutic targets Yijie Chen, Bei Jia, Xin Tong, Shengxia Yin, Wenjing Ni, Qianwen Zhao, Junping Shi, Jie Li Hepatology Communications.2025;[Epub] CrossRef
Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Coronary Artery Calcification among Filipino Patients in a Tertiary Hospital in Cebu City Mary Grace S Nepomuceno, Michael Albert M Diy, Aileen Mae L Catapang Philippine Journal of Internal Medicine.2025; 63(1): 39. CrossRef
Pre-MASLD: Should it be defined separately? Hang-Kai Huang, You-Ming Li, Cheng-Fu Xu Hepatobiliary & Pancreatic Diseases International.2024; 23(1): 1. CrossRef
Object detection: A novel AI technology for the diagnosis of hepatocyte ballooning Tian‐Lei Zheng, Jun‐Cheng Sha, Qian Deng, Shi Geng, Shu‐Yuan Xiao, Wen‐Jun Yang, Christopher D. Byrne, Giovanni Targher, Yang‐Yang Li, Xiang‐Xue Wang, Di Wu, Ming‐Hua Zheng Liver International.2024; 44(2): 330. CrossRef
Steatotic liver disease, MASLD and risk of chronic kidney disease Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, Giovanni Targher Diabetes & Metabolism.2024; 50(1): 101506. CrossRef
Role of autophagy in betaine-promoted hepatoprotection against non-alcoholic fatty liver disease in mice Jinuk Seo, Doyoung Kwon, Sou Hyun Kim, Mi Ran Byun, Yun-Hee Lee, Young-Suk Jung Current Research in Food Science.2024; 8: 100663. CrossRef
Taohe Chengqi decoction alleviated metabolic-associated fatty liver disease by boosting branched chain amino acids catabolism in the skeletal muscles of type 2 diabetes mellitus Ziqiao Yuan, Hui Qiao, Ziwei Wang, Haoran Wang, Mingru Han, Wenzhou Zhang, Yang Zhou, Hozeifa Mohamed Hassan, Wen Zhao, Tingting Qin Phytomedicine.2024; 126: 155315. CrossRef
Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice Hassam Ali, Muhammad Shahzil, Vishali Moond, Maria Shahzad, Abhay Thandavaram, Alina Sehar, Haniya Waseem, Taha Siddiqui, Dushyant Singh Dahiya, Pratik Patel, Hans Tillmann Journal of Personalized Medicine.2024; 14(1): 61. CrossRef
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim Metabolism.2024; 152: 155789. CrossRef
Performance Evaluation of a Novel Non-Invasive Test for the Detection of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease Anna Stefanska, Katarzyna Bergmann, Szymon Suwała, Aneta Mankowska-Cyl, Marek Kozinski, Roman Junik, Magdalena Krintus, Mauro Panteghini Metabolites.2024; 14(1): 52. CrossRef
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang, Tyng‐Yuan Jang, Po‐Yao Hsu, Pei‐Chien Tsai, Yu‐Ju Wei, Ming‐Lun Yeh, Ming‐Yen Hsieh, Yi‐Hung Lin, Chao‐Kuan Huang, Chia‐Yen Dai, Jee‐Fu Huang, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(4): 374. CrossRef
Time-restricted eating and supervised exercise for improving hepatic steatosis and cardiometabolic health in adults with obesity: protocol for the TEMPUS randomised controlled trial Alba Camacho-Cardenosa, Antonio Clavero-Jimeno, Juan J Martin-Olmedo, Francisco Amaro-Gahete, Rocío Cupeiro, María Trinidad González Cejudo, Patricia Virginia García Pérez, Carlos Hernández-Martínez, Raquel Sevilla-Lorente, Alejandro De-la-O, Alejandro Ló BMJ Open.2024; 14(1): e078472. CrossRef
Association of sex-specific body mass index and waist circumference trajectories with non-alcoholic fatty liver disease incidence based on growth mixture modeling Tengrui Cao, Chao Tong, Qiang Li, Yumei Han, Aheyeerke Halengbieke, Xuetong Ni, Bo Gao, Deqiang Zheng, Xinghua Yang Nutrition, Metabolism and Cardiovascular Diseases.2024; 34(5): 1245. CrossRef
Increased risk of colorectal adenomas with metabolic-associated fatty liver disease components Dongsheng Ran, ChunLing Xin, Yingcai Ma, Yanyan Lu Clinics and Research in Hepatology and Gastroenterology.2024; 48(3): 102302. CrossRef
A Cross-Sectional Investigation for Prevalence and Risk Factors of Non-Alcoholic Fatty Liver Disease in Tibetan College Students in Mainland 娟 周 Advances in Clinical Medicine.2024; 14(02): 2843. CrossRef
The Global Epidemic of Metabolic Fatty Liver Disease Ethan C. Z. Lee, Vickram V. Anand, Alex C. Razavi, Pamela L. Alebna, Mark D. Muthiah, Mohammad S. Siddiqui, Nicholas W. S. Chew, Anurag Mehta Current Cardiology Reports.2024; 26(4): 199. CrossRef
Liver sinusoidal endothelial cells as potential drivers of liver fibrosis (Review) Jiaqin Gao, Bin Zuo, Yang He Molecular Medicine Reports.2024;[Epub] CrossRef
Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration Evgenia Koureta, Evangelos Cholongitas Frontiers in Pharmacology.2024;[Epub] CrossRef
Association between remnant cholesterol and insulin resistance levels in patients with metabolic-associated fatty liver disease Shuang Wang, Qiang Zhang, Bo Qin Scientific Reports.2024;[Epub] CrossRef
Identification of crosstalk genes relating to ECM‐receptor interaction genes in MASH and DN using bioinformatics and machine learning Chao Chen, Yuxi He, Ying Ni, Zhanming Tang, Wensheng Zhang Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, Terry Cheuk‐Fung Yip, Grace Lai‐Hung Wong, Pei‐Wu Zhu, Sui‐Dan Chen, Morten Karsdal, Diana Julie Leeming, Pei Jiang, Cong Wang, Qiang Chen, Christopher D. Byrne, Giovanni Targher, Mohammed Eslam, Jacob Georg Liver International.2024; 44(5): 1129. CrossRef
Non-invasive diagnosis of non-alcoholic fatty liver disease: Current status and future perspective Jia-Lan Wang, Su-Wen Jiang, Ai-Rong Hu, Ai-Wu Zhou, Ting Hu, Hong-Shan Li, Ying Fan, Ken Lin Heliyon.2024; 10(5): e27325. CrossRef
Association of multiple serum minerals and vitamins with metabolic dysfunction-associated fatty liver disease in US adults: National Health and Nutrition Examination Survey 2017–2018 Peisen Guo, Jiahui Yu Frontiers in Nutrition.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies Khamis Al Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, Angelo Maria Patti, Khalid Al Waili, Khalid Al Rasadi, Marcello Ciaccio, Manfredi Rizzo Frontiers in Nutrition.2024;[Epub] CrossRef
Depression and hepatobiliary diseases: a bidirectional Mendelian randomization study Yu Kong, Zhongcai Yao, Lingli Ren, Liqin Zhou, Jinkai Zhao, Yuanyuan Qian, Dayong Lou Frontiers in Psychiatry.2024;[Epub] CrossRef
A universal plasma metabolites-derived signature predicts cardiovascular disease risk in MAFLD Zhonglin Li, Rui Gong, Huikuan Chu, Junchao Zeng, Can Chen, Sanping Xu, Lilin Hu, Wenkang Gao, Li Zhang, Hang Yuan, Zilu Cheng, Cheng Wang, Meng Du, Qingjing Zhu, Li Zhang, Lin Rong, Xiaoqing Hu, Ling Yang Atherosclerosis.2024; 392: 117526. CrossRef
Hydroxytyrosol Linoleoyl Ether Ameliorates Metabolic-Associated Fatty Liver Disease Symptoms in Obese Zucker Rats Rubén Tovar, Marialuisa de Ceglia, Miguel Rodríguez-Pozo, Antonio Vargas, Ana Gavito, Juan Suárez, Anna Boronat, Rafael de la Torre, Fernando Rodríguez de Fonseca, Elena Baixeras, Juan Decara ACS Pharmacology & Translational Science.2024; 7(5): 1571. CrossRef
Type 1 diabetes mellitus and non-alcoholic fatty liver disease: a two-sample Mendelian randomization study Lin Tuo, Li-ting Yan, Yi Liu, Xing-xiang Yang Frontiers in Endocrinology.2024;[Epub] CrossRef
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective Yansong Fu, Zhipeng Wang, Hong Qin Metabolites.2024; 14(4): 218. CrossRef
Evidence related to a vegetarian diet and metabolic dysfunction-associated steatotic liver disease: protocol for a scoping review Kasey Moss, Victor Gitman, M Ines Pinto Sanchez, Simon Oczkowski, David Armstrong, Saumya Jayakumar, Constantine Jason Karvellas, Nazia Selzner, Joanna Dionne BMJ Open.2024; 14(4): e079750. CrossRef
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn Liver Cancer.2024; 13(5): 561. CrossRef
Prevalence of Nonalcoholic Fatty Liver Disease [NAFLD] and Metabolic dysfunction associated Fatty Liver Disease [MAFLD] in patients with Irritable Bowel Syndrome [IBS] Md. Musab Khalil, Sirajam Munira, Md. Mahbubul Alam, Al Mahmood Appolo, Musatafa Md. Abu Sayeed, Atikul Islam, Narwana Khaleque, Mohammad Faisal, Arifa Tasnim, Ruma Najnin, Mahmudur Rahman, Enamul Karim, Md. Golam Kibria SN Comprehensive Clinical Medicine.2024;[Epub] CrossRef
Positive association between insulin resistance and fatty liver disease in psoriasis: evidence from a cross-sectional study Xiaoyuan Zhong, Dawei Huang, Rongfen Chen, Lingling Yao, Rui Ma, Yingyuan Yu, Yuxiong Jiang, Luyang Kong, Jiajing Lu, Ying Li, Yuling Shi Frontiers in Immunology.2024;[Epub] CrossRef
Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population Young Lee, Eun Ju Cho, Eun Kyung Choe, Min-Sun Kwak, Jong In Yang, Seung-Won Oh, Jeong Yoon Yim, Goh Eun Chung Scientific Reports.2024;[Epub] CrossRef
Essential Oils for the Treatment and Management of Nonalcoholic Fatty Liver Disease (NAFLD) Taehwa Kim, Mohammad Al Mijan, Jeonga Lee, Jungmi Yun, Jae Heun Chung, Soo Min Son, Ryuk Jun Kwon Natural Product Communications.2024;[Epub] CrossRef
The Role of PNPLA3_rs738409 Gene Variant, Lifestyle Factors, and Bioactive Compounds in Nonalcoholic Fatty Liver Disease: A Population-Based and Molecular Approach towards Healthy Nutrition Meiling Liu, Sunmin Park Nutrients.2024; 16(8): 1239. CrossRef
Prevalence of metabolic dysfunction-associated fatty liver disease and its association with glycemic control in persons with type 2 diabetes in Africa: A systematic review and meta-analysis Emmanuel Ekpor, Samuel Akyirem, Precious Adade Duodu, Bert B. Little PLOS Global Public Health.2024; 4(5): e0002835. CrossRef
Role of FXR in the development of NAFLD and intervention strategies of small molecules Jiachan Long, Yuanhang Xu, Xuerong Zhang, Bingxing Wu, Caiyan Wang Archives of Biochemistry and Biophysics.2024; 757: 110024. CrossRef
Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum Josep León-Mengíbar, Enric Sánchez, Ferrán Herrerías, Mari Cruz De La Fuente, Maite Santamaría, José Manuel Valdivielso, Marcelino Bermúdez-López, Eva Castro, Judit Pallarés, Xavier Matias-Guiu, Felip Vilardell, Assumpta Caixàs, Marta Bueno, Raquel Martí, Frontiers in Endocrinology.2024;[Epub] CrossRef
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective Shelley E. Keating, Yogesh Chawla, Arka De, Elena S. George Hepatology International.2024; 18(S2): 959. CrossRef
Early life exposure to vitamin D deficiency impairs molecular mechanisms that regulate liver cholesterol biosynthesis, energy metabolism, inflammation, and detoxification Megan M. Knuth, Jing Xue, Marwa Elnagheeb, Raad Z. Gharaibeh, Sarah A. Schoenrock, Susan McRitchie, Cory Brouwer, Susan J. Sumner, Lisa Tarantino, William Valdar, R. Scott Rector, Jeremy M. Simon, Folami Ideraabdullah Frontiers in Endocrinology.2024;[Epub] CrossRef
Deconvolution analysis identified altered hepatic cell landscape in primary sclerosing cholangitis and primary biliary cholangitis Hoang Nam Pham, Linh Pham, Keisaku Sato Frontiers in Medicine.2024;[Epub] CrossRef
Letter to the editor: Comment on “The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – A four-arm randomized controlled trial” Luping Quan, Chao Ding, Yumeng Jin, Yaping Li Clinical Nutrition.2024; 43(6): 1595. CrossRef
Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case–control study and serological comparison Zheng Lin, Yue-yi Shi, Lu-yan Yu, Chen-xi Ma, Si-yi Pan, Yuan Dou, Qiu-jun Zhou, Yi Cao Frontiers in Medicine.2024;[Epub] CrossRef
Age at menopause and risk of metabolic dysfunction-associated fatty liver disease: A 14-year cohort study Ehn-Young Kim, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee Digestive and Liver Disease.2024; 56(11): 1880. CrossRef
MAFLD and glomerular hyperfiltration in subjects with normoglycemia, prediabetes and type 2 diabetes: A cross‐sectional population study Manuela Abbate, Aneliya Parvanova, Ángel Arturo López‐González, Aina M. Yañez, Miquel Bennasar‐Veny, José Ignacio Ramírez‐Manent, Elia Reseghetti, Piero Ruggenenti Diabetes/Metabolism Research and Reviews.2024;[Epub] CrossRef
Associations of perfluoroalkyl substances with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2017–2018 Yuxiao Zhang, Min Zhang, Shanjiamei Jiang, Heng Hu, Xinzhi Wang, Fan Yu, Yue’e Huang, Yali Liang Cancer Causes & Control.2024; 35(9): 1271. CrossRef
Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies Pegah Golabi, Soroor Owrangi, Zobair M. Younossi Alimentary Pharmacology & Therapeutics.2024;[Epub] CrossRef
Azorella compacta Organic Extracts Exacerbate Metabolic Dysfunction-Associated Fatty Liver Disease in Mice Fed a High-Fat Diet Jessica Zúñiga-Hernandez, Matías Quiñones San Martin, Benjamín Figueroa, Ulises Novoa, Francisco A. Monsalve, Mitchell Bacho, Aurelio San-Martin, Daniel R. González Pharmaceuticals.2024; 17(6): 746. CrossRef
Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β Joey A. Muns, Erik Schooten, Rychon D. J. van Dasselaar, Yvet E. Noordman, Kevin Adamzek, Arthur C. Eibergen, Sebas D. Pronk, Sagel Cali, Niels J. Sijbrandi, Eugen Merkul, Sabrina Oliveira, Paul M.P. van Bergen en Henegouwen, R. Bart Takkenberg, Joanne Ve European Journal of Nuclear Medicine and Molecular Imaging.2024; 51(12): 3545. CrossRef
Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD Jin Imai, Shinji Takashimizu, Nana Suzuki, Kana Ohshinden, Kana Sawamoto, Yusuke Mishima, Kota Tsuruya, Yoshitaka Arase, Mitsuhiko Yamano, Noriaki Kishimoto, Chizumi Yamada, Nagamu Inoue, Kengo Moriyama, Akiyasu Baba, Hidekazu Suzuki, Tatehiro Kagawa, Yas Scientific Reports.2024;[Epub] CrossRef
Ultrasound Shear Wave Elastography Evaluation of the Liver and Implications for Perioperative Medicine Giancarlo Suffredini, Wei Dong Gao, Jeffrey M. Dodd-o Journal of Clinical Medicine.2024; 13(13): 3633. CrossRef
Importance of the gut microbiota in the gut-liver axis in normal and liver disease Stanislav Kotlyarov World Journal of Hepatology.2024; 16(6): 878. CrossRef
Interplay of Mediterranean-diet adherence, genetic factors, and metabolic dysfunction-associated steatotic liver disease risk in Korea Yu-Jin Kwon, Ja-Eun Choi, Kyung-Won Hong, Ji-Won Lee Journal of Translational Medicine.2024;[Epub] CrossRef
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef
Breaking Barriers: Enhancing Statins Utilization for Cardiovascular Protection in MAFLD Faraz Arshad The American Journal of Medicine.2024; 137(7): e142. CrossRef
Insight into the regulatory mechanism of m6A modification: From MAFLD to hepatocellular carcinoma Xuan Zha, Zewei Gao, Min Li, Xueli Xia, Zhenwei Mao, Shengjun Wang Biomedicine & Pharmacotherapy.2024; 177: 116966. CrossRef
Alanine aminotransferase predicts incident steatotic liver disease of metabolic etiology: Long life to the old biomarker! Amedeo Lonardo World Journal of Gastroenterology.2024; 30(24): 3016. CrossRef
Proinflammatory interleukins 2, 6 and tumor necrosis factor alpha in patients with hypertension and diabetes mellitus depending on the presence of metabolic-associated liver steatosis O.M. Radchenko, O.J. Komarytsia, M.O. Borovets, R.S. Ivasivka, R.R. Guta INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(3): 200. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Gastroenterology.2024; 84(1): 1. CrossRef
Disinfection Byproducts of Haloacetaldehydes Disrupt Hepatic Lipid Metabolism and Induce Lipotoxicity in High-Fat Culture Conditions Lili Yang, Zhiqiang Jiang, Lan Yang, Weiwei Zheng, Yu Chen, Fei Qu, M. James C. Crabbe, Yubin Zhang, Melvin E. Andersen, Yuxin Zheng, Weidong Qu Environmental Science & Technology.2024; 58(28): 12356. CrossRef
Association between life’s essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults Zheng Wang, Bohan Huang, Yixuan Ding, Feng Cao, Fei Li, Prof Fei Li Archives of Public Health.2024;[Epub] CrossRef
Metformin Lowers Plasma Triacylglycerol Levels in Mice with Impaired Carnitine Biosynthesis and Fatty Liver Bodil Bjørndal, Tra-My Thi Le, Elin Strand, Lise Madsen, Rolf K. Berge SynBio.2024; 2(3): 240. CrossRef
The Role of Antioxidants in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease: A Systematic Review Kiana Mohammadian, Fatemeh Fakhar, Shayan Keramat, Agata Stanek Antioxidants.2024; 13(7): 797. CrossRef
Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease Mohammadjavad Sotoudeheian Protein & Peptide Letters.2024; 31(4): 290. CrossRef
In vitro osteoclast differentiation enhanced by hepatocyte supernatants from high-fat diet mice Yan Wang, Fangli Zhou, Siyi Shu, Yunhong Wu, Haoming Tian, Yujue Li, Xiang Chen Biochemistry and Biophysics Reports.2024; 39: 101788. CrossRef
Novel insights into autophagy in gastrointestinal pathologies, mechanisms in metabolic dysfunction-associated fatty liver disease and acute liver failure Tsvetelina Velikova, Milena Gulinac World Journal of Gastroenterology.2024; 30(27): 3273. CrossRef
The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review Liana Iordan, Laura Gaita, Romulus Timar, Vlad Avram, Adrian Sturza, Bogdan Timar International Journal of Molecular Sciences.2024; 25(13): 7057. CrossRef
Genotypic variation in CYP2E1, GCKR, and PNPLA3 among nonalcoholic steatohepatitis patients of Turkish origin Abbas Ali Husseini Molecular Biology Reports.2024;[Epub] CrossRef
Hepatic Steatosis Can Be Partly Generated by the Gut Microbiota–Mitochondria Axis via 2-Oleoyl Glycerol and Reversed by a Combination of Soy Protein, Chia Oil, Curcumin and Nopal Mónica Sánchez-Tapia, Sandra Tobón-Cornejo, Lilia G. Noriega, Natalia Vázquez-Manjarrez, Diana Coutiño-Hernández, Omar Granados-Portillo, Berenice M. Román-Calleja, Astrid Ruíz-Margáin, Ricardo U. Macías-Rodríguez, Armando R. Tovar, Nimbe Torres Nutrients.2024; 16(16): 2594. CrossRef
TG: HDL, AST: ALT, A:G Ratios in Alcoholic and Non-alcoholic Fatty Liver patients Abhinav Manish, Anuradha Bharosay, Kanchan Negi, Ritesh Srivastava Journal of Research in Applied and Basic Medical Sciences.2024; 10(3): 279. CrossRef
Protective effects of syringic acid in nonalcoholic fatty liver in rats through regulation of Nrf2/HO‐1 signaling pathway Simiao Zhang, Sheng Zheng, Ya Li, Juan Yang, Xiaozhou Mao, Tao Liu, Qiuxin Zhang, ZhiPeng Fu, Xing Zhu, Long Xu Journal of Biochemical and Molecular Toxicology.2024;[Epub] CrossRef
SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis Ileana Mendez Espinoza, Elijah N. D. Choos, Carolyn M. Ecelbarger, Blythe D. Shepard American Journal of Physiology-Gastrointestinal and Liver Physiology.2024; 327(2): G235. CrossRef
Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation Hiroki Yanagisawa, Hitoshi Maeda, Isamu Noguchi, Motohiko Tanaka, Naoki Wada, Taisei Nagasaki, Kazuki Kobayashi, Gai Kanazawa, Kazuaki Taguchi, Victor Tuan Giam Chuang, Hiromi Sakai, Hiroyuki Nakashima, Manabu Kinoshita, Hiroaki Kitagishi, Yasuko Iwakiri, Redox Biology.2024; 76: 103314. CrossRef
Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD I Sabinari, O Horakova, T Cajka, V Kleinova, MR Wieckowski, M Rossmeisl Physiological Research.2024; (Suppl 1): S295. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Medicine.2024; 99(4): 189. CrossRef
Effect of Ilex hainanensis Merr. On HFD-induced nonalcoholic fatty liver disease and rebalance of gut microbiota and bile acids metabolism in mice Jia-yi Tian, Meng Xiao, Wen-wen Zhao, Xia Wu, Jie Yang, Xiao-qing Chen Fitoterapia.2024; 178: 106186. CrossRef
The interplay of extracellular vesicles in the pathogenesis of metabolic impairment and type 2 diabetes Lorenzo Carciero, Gianfranco Di Giuseppe, Eleonora Di Piazza, Erfan Parand, Laura Soldovieri, Gea Ciccarelli, Michela Brunetti, Antonio Gasbarrini, Enrico C. Nista, Giovambattista Pani, Alfredo Pontecorvi, Andrea Giaccari, Teresa Mezza Diabetes Research and Clinical Practice.2024; 216: 111837. CrossRef
Additive effect of metabolic dysfunction-associated fatty liver disease on left ventricular function and global strain in type 2 diabetes mellitus patients: a 3.0 T cardiac magnetic resonance feature tracking study Xin Tang, Rui Shi, Li Jiang, Wei-Feng Yan, Pei-Lun Han, Wen-Lei Qian, Zhi-Gang Yang, Yuan Li Cardiovascular Diabetology.2024;[Epub] CrossRef
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef
Asperuloside activates hepatic NRF2 signaling to stimulate mitochondrial metabolism and restore lipid homeostasis in high fat diet-induced MAFLD Chufeng He, Qile Zhang, Ruiwen Zhu, Gary Tse, Wing Tak Wong European Journal of Pharmacology.2024; 983: 177003. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
3,5-Dimethyl-2,4,6-trimethoxychalcone Lessens Obesity and MAFLD in Leptin-Deficient ob/ob Mice Stéphanie Gaigé, Anne Abysique, Rym Barbouche, Alain Tonetto, Attilio Di Maio, Maxime Robin, Anh-Tuan Lormier, Jean-Denis Troadec International Journal of Molecular Sciences.2024; 25(18): 9838. CrossRef
Novel eicosanoid signature in plasma provides diagnostic for metabolic dysfunction-associated steatotic liver disease Oswald Quehenberger, Aaron M. Armando, Tiffany H. Cedeno, Rohit Loomba, Arun J. Sanyal, Edward A. Dennis Journal of Lipid Research.2024; 65(10): 100647. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung Cancers.2024; 16(18): 3161. CrossRef
Comprehensive RNA-Seq Gene Co-Expression Analysis Reveals Consistent Molecular Pathways in Hepatocellular Carcinoma across Diverse Risk Factors Nicholas Dale D. Talubo, Po-Wei Tsai, Lemmuel L. Tayo Biology.2024; 13(10): 765. CrossRef
Tea intake and non-alcoholic fatty liver disease risk: A two-sample Mendelian randomization study Cuncun Lu, Lixin Ke, Alexios-Fotios A. Mentis, Qiang Zhang, Ziyi Wang, Zhifei Wang Metabolism Open.2024; 24: 100322. CrossRef
Significance of Immune and Non-Immune Cell Stroma as a Microenvironment of Hepatocellular Carcinoma—From Inflammation to Hepatocellular Carcinoma Progression Jacek Baj, Magdalena Kołodziej, Joanna Kobak, Jacek Januszewski, Kinga Syty, Piero Portincasa, Alicja Forma International Journal of Molecular Sciences.2024; 25(19): 10233. CrossRef
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review Haixiang Zheng, Leonardo Antonio Sechi, Eliano Pio Navarese, Gavino Casu, Gianpaolo Vidili Cardiovascular Diabetology.2024;[Epub] CrossRef
A new Korean nomenclature for steatotic liver disease
Clinical and Molecular Hepatology.2024; 30(Suppl): S214. CrossRef
Association of niacin intake and metabolic dysfunction-associated steatotic liver disease: findings from National Health and Nutrition Examination Survey Jing Zhou, Jun Han BMC Public Health.2024;[Epub] CrossRef
Impact of High-Temperature Feeds on Gut Microbiota and MAFLD Lijun Xue, Kaimin Li, Yanfei Jia, Dongxue Yao, Xuexing Guo, Shuhong Zhang Journal of Microbiology and Biotechnology.2024; 34(9): 1789. CrossRef
Recent Trends in Liver Cancer: Epidemiology, Risk Factors, and Diagnostic Techniques Shivani R Kale, Geeta Karande, Anand Gudur, Aishwarya Garud, Monika S Patil, Satish Patil Cureus.2024;[Epub] CrossRef
Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease:
Detecting Advanced Fibrosis based on Reported Liver Stiffness
Measurement in FibroScan and Laboratory Findings Mohammadjavad Sotoudeheian The International Journal of Gastroenterology and Hepatology Diseases.2024;[Epub] CrossRef
Higher Adherence to the Mediterranean Diet Is Associated with a Lower Risk of Steatotic, Alcohol-Related, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Analysis Ji Lee, Sue Kim, Yaeji Lee, Yu-Jin Kwon, Ji-Won Lee Nutrients.2024; 16(20): 3551. CrossRef
Day napping and metabolic-associated fatty liver disease: A systematic review and meta-analysis of observational studies Linxiao Gao, Jianping Gong, Guochao Zhong, Yajun Qin Medicine.2024; 103(44): e40362. CrossRef
Unbiased and reproducible liver MRI-PDFF estimation using a scan protocol-informed deep learning method Juan P. Meneses, Ayyaz Qadir, Nirusha Surendran, Cristobal Arrieta, Cristian Tejos, Marcelo E. Andia, Zhaolin Chen, Sergio Uribe European Radiology.2024; 35(5): 2843. CrossRef
Oxylipins Derived from PUFAs in Cardiometabolic Diseases: Mechanism of Actions and Possible Nutritional Interactions Duygu Ağagündüz, Özge Yeşildemir, Emine Koçyiğit, Tevfik Koçak, Buket Özen Ünaldı, Gamze Ayakdaş, Ferenc Budán Nutrients.2024; 16(22): 3812. CrossRef
Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022 Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang The Korean Journal of Internal Medicine.2024; 39(6): 931. CrossRef
ASPP2 deficiency promotes the progression of metabolic dysfunction-associated steatohepatitis via ACSL4 upregulation Jinming Wang, Quanwei Li, Yunfei Huo, Xiaoni Liu, Ying Shi, Bangxiang Xie Scientific Reports.2024;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won- Diabetes & Metabolism Journal.2024; 48(6): 1015. CrossRef
Exploring the relationship between air pollution, non-alcoholic fatty liver disease, and liver function indicators: a two-sample Mendelian randomization analysis study Qingliang Song, Jinyue Pan, Maoxing Pan, Chuiyang Zheng, Wen Fan, Jianwei Zhen, Dajin Pi, Zheng Liang, Haiyan Shen, Yuanyou Li, Qinhe Yang, Yupei Zhang Frontiers in Endocrinology.2024;[Epub] CrossRef
Western diet promotes the progression of metabolic dysfunction‐associated steatotic liver disease in association with ferroptosis in male mice Nicole Maddie, Nefia Chacko, David Matatov, Maria Alicia Carrillo‐Sepulveda Physiological Reports.2024;[Epub] CrossRef
Coriandrum sativum L. Leaf Extract Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating the AMPK Pathway in High Fat-Fed C57BL/6 Mice Min Ji Gu, Yejin Ahn, Yu Ra Lee, Guijae Yoo, Yoonsook Kim, Inwook Choi, Sang Keun Ha, Donghwan Kim Nutrients.2024; 16(23): 4165. CrossRef
Comparative analysis of NAFLD-related health videos on TikTok: a cross-language study in the USA and China Hongyu Wu, Jialun Peng, Shengwei Li, Xiong Ding, Tao Zhong, Qilong Zhai, Changjie Du, Jiajun Yuan, Can Cai, Jinzheng Li BMC Public Health.2024;[Epub] CrossRef
Metabolic syndrome therapy in pediatric age — between classic and modern. From diets to pipeline drugs Otilia Elena Frăsinariu, Vasile Valeriu Lupu, Laura Mihaela Trandafir, Violeta Streanga, Elena Jechel, Iris Bararu-Bojan, Ioana Vasiliu, Magdalena Cuciureanu, Isabela Ioana Loghin, Costica Mitrofan, Alin Horatiu Nedelcu, Anton Knieling, Ancuta Lupu Frontiers in Nutrition.2024;[Epub] CrossRef
Triglycerides to apolipoprotein A1 ratio: an effective insulin resistance-associated index in identifying metabolic dysfunction-associated fatty liver disease in type 2 diabetes mellitus Wei Wang, Yang Chen, Mei Tu, Hang Ju Chen Frontiers in Endocrinology.2024;[Epub] CrossRef
Does metabolic dysfunction-associated fatty liver disease increase the risk of chronic kidney disease? A meta-analysis of cohort studies Wanghao Liu, Xiaoying Sun BMC Nephrology.2024;[Epub] CrossRef
Association between the ratio of serum uric acid to high-density lipoprotein cholesterol and liver fat content: evidence from a Chinese health examination dataset Ao Liu, Yongbing Sun, Xin Qi, Yang Zhou, Jing Zhou, Zhonglin Li, Xiaoling Wu, Zhi Zou, Xue Lv, Hao Li, Yongli Li Scientific Reports.2024;[Epub] CrossRef
Association of serum selenium with MASLD and liver fibrosis: A cross-sectional study Wenying Guo, Ting Weng, Yufei Song, Anna Di Sessa PLOS ONE.2024; 19(12): e0314780. CrossRef
Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Associati Magdalena Olszanecka-Glinianowicz, Artur Mazur, Jerzy Chudek, Beata Kos-Kudła, Leszek Markuszewski, Dominika Dudek, Piotr Major, Piotr Małczak, Wiesław Tarnowski, Paweł Jaworski, Elżbieta Tomiak Nutrients.2023; 15(7): 1641. CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef
Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski International Journal of Molecular Sciences.2023; 24(11): 9677. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef
Metabolic dysfunction: The silenced connection with fatty liver disease Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, Manuel Romero-Gómez, Mohammed Eslam, Nahum Méndez-Sánchez Annals of Hepatology.2023; 28(6): 101138. CrossRef
MAFLD: an optimal framework for understanding liver cancer phenotypes Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George Journal of Gastroenterology.2023; 58(10): 947. CrossRef
Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease Chuan Lu, Yan Chen, Yue Zhang, Xin Zhao Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2627. CrossRef
Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease Rachmad Anres Dongoran, Fang-Cen Tu, Chin-Hung Liu Tzu Chi Medical Journal.2023; 35(4): 290. CrossRef
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk Keungmo Yang, Myeongjun Song Nutrients.2023; 15(18): 3970. CrossRef
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, Theocharis Koufakis, Ioannis G. Lempesis, Eleni Papantoniou, Georgios Kalopitas, Vasiliki E. Georgakopoulou, Ioanna E. Stergiou, Stamatios Theocharis, Georgios Germanidis International Journal of Molecular Sciences.2023; 24(19): 14704. CrossRef
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień Medicina.2023; 59(10): 1789. CrossRef
Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus Alessandro Csermely, Alessandro Mantovani, Mario Luca Morieri, Luisa Palmisano, Maria Masulli, Efisio Cossu, Marco Giorgio Baroni, Katia Bonomo, Flavia Agata Cimini, Gisella Cavallo, Raffaella Buzzetti, Carmen Mignogna, Frida Leonetti, Simonetta Bacci, Ro Diabetes & Metabolism.2023; 49(6): 101477. CrossRef
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity Gi-Ae Kim, Joon Ho Moon, Won Kim Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials Ming-Lun Yeh, Ming-Lung Yu Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef
The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers Amedeo Lonardo Expert Review of Clinical Pharmacology.2023; 16(10): 891. CrossRef
Vascular calcification: from the perspective of crosstalk Shiqi Yang, Zhaolin Zeng, Qing Yuan, Qian Chen, Zuo Wang, Hui Xie, Jianghua Liu Molecular Biomedicine.2023;[Epub] CrossRef
What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez Current Hepatology Reports.2023; 22(4): 221. CrossRef
Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease Divyavani Gowda, Chandra Shekhar, Siddabasave Gowda B. Gowda, Yifan Chen, Shu-Ping Hui Livers.2023; 3(4): 687. CrossRef
Biological Role and Related Natural Products of SIRT1 in Nonalcoholic Fatty Liver Decheng Meng, Fengxia Zhang, Wenfei Yu, Xin Zhang, Guoliang Yin, Pengpeng Liang, Yanan Feng, Suwen Chen, Hongshuai Liu Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4043. CrossRef
Recent Updates on the Therapeutic Prospects of Reversion-Inducing Cysteine-Rich Protein with Kazal Motifs (RECK) in Liver Injuries Giuseppina Palladini, Laura Giuseppina Di Pasqua, Anna Cleta Croce, Andrea Ferrigno, Mariapia Vairetti International Journal of Molecular Sciences.2023; 24(24): 17407. CrossRef
Association between carotenoid intake and metabolic dysfunction-associated fatty liver disease among US adults: A cross-sectional study Hang Zhang, Li Li, Lei Jia, Jinchun Liu Medicine.2023; 102(51): e36658. CrossRef
Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight individuals. However, there is no standard definition of this unique phenotype. Second, fatty liver is often observed in patients with concomitant viral hepatitis. The exclusion of viral hepatitis from non-alcoholic fatty liver disease limits its value and detracts from the investigation and holistic management of coexisting fatty liver in patients with viral hepatitis. Third, fatty liver-associated hepatocellular carcinoma (HCC) is generally categorized as non-B non-C HCC. Fourth, the population is aging rapidly, and it is imperative to develop a practicable, low-intensity exercise program for elderly patients. Fifth, most patients and nonspecialized healthcare professionals still lack an awareness of the significance of fatty liver both in terms of intrahepatic and extrahepatic disease and cancer. Recently, an international expert panel proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). One feature of MAFLD is that metabolic dysfunction is a prerequisite for diagnosis. Pertinent to regional issues, MAFLD also provides its diagnostic criteria in lean/normal-weight individuals. Furthermore, MAFLD is independent of any concomitant liver disease, including viral hepatitis. Therefore, MAFLD may be a more suitable definition for fatty liver in the Asia-Pacific region. In this review, we introduce the regional characteristics of fatty liver and discuss the advantages of MAFLD for improving clinical practice for liver disease in the region.
Citations
Citations to this article as recorded by
The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial Chih-Lin Lin, Wei-You Li, Shang-Jung Wu, Patricia M. T. Chen, Allan Y. Chen, Cathy Shen-Jang Fann, Yi-Ming Arthur Chen International Journal of Molecular Sciences.2026; 27(5): 2411. CrossRef
Central obesity measured by weight-adjusted waist index is associated with lean MASLD Ziteng Wang, Wentao Tan, Zhe Yu, Herui Wei, Jing Luo, Wen An, Mengqi Li, Qi Gao, Lijuan Sun, Aqian Song, Lingling He, Jiali Ma, Fan Xiao, Hong Liu, Hui Zhong, Hongshan Wei Clinics and Research in Hepatology and Gastroenterology.2026; 50(5): 102822. CrossRef
Asia-Pacific perspectives on the steatotic liver disease (SLD) reclassification: balancing terminology, diagnostic criteria, and implementation Kuo Chao Yew, Quan Rui Tan, Bernett Lee, Sunny Hei Wong, Lung Yi Mak, Rashid N Lui, George Boon-Bee Goh, Dewi Norwani Basir, Sakkarin Chirapongsathorn, Jian-Gao Fan, Seung Up Kim, Ming-Lung Yu, Vincent Wai-Sun Wong, Hazel H Oon Annals of Hepatology.2026; : 102255. CrossRef
Pemafibrate Reduced Liver Stiffness in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Complicated with Hyperlipidemia and Liver Fibrosis with a Fibrosis-4 Index Above 1.3 Tatsuki Ichikawa, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura, Naohiro Komatsu, Sayuri Sugio, Miruki Yoshino, Hisamitsu Miyaaki Internal Medicine.2025; 64(9): 1296. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism Irene Tizianel, Alberto Madinelli, Filippo Crimì, Mattia Barbot, Simona Censi, Chiara Sabbadin, Filippo Ceccato Clinical Endocrinology.2025; 102(6): 618. CrossRef
Liver disease trends in the Asia-Pacific region for the next 50 years Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(3): 671. CrossRef
A vegetarian diet improves hepatic steatosis in MASLD patients through weight loss: a randomized controlled trial in China Xiaomeng Mao, Kaijie Xu, Cenyu Wang, Xintong Lu, Xinyuan Yao, Fangfang Song, Zhiping Yu, Linxi Qian, Yi Feng, Xiuhua Shen Food & Function.2025; 16(19): 7678. CrossRef
Emerging roles of stress granules in liver diseases: a comprehensive review Qianyun Zhang, Yun Liu, Junzhe Tang, Ming Li, Qiang Jia Frontiers in Cell and Developmental Biology.2025;[Epub] CrossRef
Prevalence of Non-alcoholic Fatty Liver Disease Detected by Computed Tomography in the General Population Compared with Ultrasonography Yuki Ito, Kentaro Yoshioka, Kazuhiko Hayashi, Yuko Shimizu, Ryo Fujimoto, Ryosuke Yamane, Michiyo Yoshizaki, Go Kajikawa, Taro Mizutani, Hidemi Goto Internal Medicine.2024; 63(2): 159. CrossRef
Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multicenter study Shuhei Fukunaga, Michita Mukasa, Tomoyuki Nakane, Dan Nakano, Tsubasa Tsutsumi, Tomonori Chou, Hiroshi Tanaka, Daiki Hayashi, Shinpei Minami, Akihiro Ohuchi, Tsutomu Nagata, Kota Takaki, Hiroshi Takaki, Ichiro Miyajima, Ryuichi Nouno, Toshihiro Araki, Tak Hepatology Research.2024; 54(2): 201. CrossRef
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study Tomoya Sano, Keisuke Amano, Tatsuya Ide, Hiroshi Isoda, Yuichi Honma, Yasuyo Morita, Yoichi Yano, Hiroki Nakamura, Satoshi Itano, Ichiro Miyajima, Miki Shirachi, Reiichiro Kuwahara, Miki Ohno, Toshihiro Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Teruko Arin Hepatology Research.2024; 54(4): 326. CrossRef
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease Hyeok-Hee Lee, Han Ah Lee, Eun-Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim Gut.2024; 73(3): 533. CrossRef
Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease Tyng‐Yuan Jang, Chi‐Chang Ho, Po‐Cheng Liang, Chih‐Da Wu, Yu‐Ju Wei, Pei‐Chien Tsai, Po‐Yao Hsu, Ming‐Yen Hsieh, Yi‐Hung Lin, Meng‐Hsuan Hsieh, Chih‐Wen Wang, Jeng‐Fu Yang, Ming‐Lun Yeh, Chung‐Feng Huang, Wan‐Long Chuang, Jee‐Fu Huang, Ya‐Yun Cheng, Chia‐ The Kaohsiung Journal of Medical Sciences.2024; 40(3): 304. CrossRef
Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma Ji-Qiao Zhu, Xiao-Yong Ye, Shi-Wei Yang, Jia-Zong Liu, Zhang-Yong Ren, Ya-Nan Jia, Zhe Liu, Cheng Ding, Jian-Tao Kou, Xian-Liang Li, Dong-Dong Han, Qiang He European Journal of Clinical Nutrition.2024; 78(2): 107. CrossRef
Influence of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with HBV-related acute-on-chronic liver failure Rui-Min Lai, Li-Xi Yao, Shan Lin, Jia-Hui Zhou, Bing-Ping Liu, Zhao-Yi Liang, Tianbin Chen, Jia-Ji Jiang, Qi Zheng, Yueyong Zhu Expert Review of Gastroenterology & Hepatology.2024; 18(1-3): 103. CrossRef
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim Metabolism.2024; 152: 155789. CrossRef
Impact of metabolic dysfunction‐associated fatty liver disease on the incidence of Helicobacter pylori‐negative gastric cancer Tomoyuki Nakane, Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Hiroshi Tanaka, Tomonori Chou, Shinpei Minami, Akihiro Ohuchi, Tsutomu Nagata, Kota Takaki, Hiroshi Takaki, Ichiro Miyajima, Ryuichi Nouno, Shinobu Yoshinaga, Michita Mukasa, Yoshinobu Okabe, Hepatology Research.2024; 54(6): 540. CrossRef
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation Byeong Hyun Min, Shivani Devi, Goo Hyun Kwon, Haripriya Gupta, Jin-Ju Jeong, Satya Priya Sharma, Sung-Min Won, Ki-Kwang Oh, Sang Jun Yoon, Hee Jin Park, Jung A Eom, Min Kyo Jeong, Ji Ye Hyun, Nattan Stalin, Tae-Sik Park, Jieun Choi, Do Yup Lee, Sang Hak H Gut Microbes.2024;[Epub] CrossRef
Association between life’s essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults Zheng Wang, Bohan Huang, Yixuan Ding, Feng Cao, Fei Li, Prof Fei Li Archives of Public Health.2024;[Epub] CrossRef
Translational research on drug development and biomarker discovery for hepatocellular carcinoma Valerie Chew, Chien-Huai Chuang, Chiun Hsu Journal of Biomedical Science.2024;[Epub] CrossRef
High prevalence of fatty liver and its association with metabolic syndrome among rural adults with chronic hepatitis C: Implications for primary healthcare Ta-Jen Wang, Mei-Yen Chen, Yu-Chih Lin, Wen-Nan Chiu, Tung-Jung Huang, Hsu-Huei Weng BMC Public Health.2024;[Epub] CrossRef
Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups Tatsuya Fukuda, Takahiro Okamoto, Takahiro Fukaishi, Akio Kawakami, Makoto Tanaka, Tetsuya Yamada, Koshiro Monzen Frontiers in Endocrinology.2024;[Epub] CrossRef
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease Ziyan Pan, Moutaz Derbala, Khalid AlNaamani, Hasmik Ghazinian, Jian-Gao Fan, Mohammed Eslam Annals of Hepatology.2024; 29(5): 101512. CrossRef
MAFLD identifies patients with significant hepatic fibrosis better than MASLD Ziyan Pan, Said A. Al-Busafi, Maheeba Abdulla, Yasser Fouad, Giada Sebastiani, Mohammed Eslam Hepatology International.2024; 18(3): 964. CrossRef
MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight Ziyan Pan, Maryam Al Khatry, Ming-Lung Yu, Ashok Choudhury, Giada Sebastiani, Saleh A. Alqahtani, Mohammed Eslam Therapeutic Advances in Endocrinology and Metabolism.2024;[Epub] CrossRef
MAFLD: from a disease framework to patient care Mohammed Eslam, Jacob George Hepatology International.2024; 18(S2): 823. CrossRef
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George Clinical and Molecular Hepatology.2024; 30(3): 436. CrossRef
Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials Takumi Kawaguchi, Kenta Murotani, Hiromitsu Kajiyama, Hitoshi Obara, Hironori Yamaguchi, Yuko Toyofuku, Fumi Kaneko, Yutaka Seino, Saeko Uchida Journal of Gastroenterology.2024; 59(9): 836. CrossRef
Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular c Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 705. CrossRef
Paradigm shift in steatotic liver disease (SLD): from NAFLD to MASLD Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, Naohiro Wada, Asako Nogami, Hirokazu Takahashi, Atsushi Nakajima Kanzo.2024; 65(9): 420. CrossRef
Overlapping group between non‐alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research Yu‐Ming Cheng, Tsung‐Han Hsieh, Chia‐Chi Wang, Jia‐Horng Kao JGH Open.2024;[Epub] CrossRef
Metabolic dysfunction-associated fatty liver disease related hepatocellular carcinoma in China: An increasing problem: Letter to the edior on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A sy Xiangyu Wu, Wenjing Ni, Qianqian Chen, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 965. CrossRef
Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan Takumi Kawaguchi, Yoshiyuki Fujishima, Daisuke Wakasugi, Fusayo Io, Yuri Sato, Saeko Uchida, Yukiko Kitajima Journal of Gastroenterology.2024; 59(12): 1120. CrossRef
Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation Ling-Ling Wang, Yu-Ming Lu, Yi-Han Wang, Yi-Fan Wang, Rong-Fei Fang, Wen-Li Sai, Deng-Fu Yao, Min Yao World Journal of Gastroenterology.2024; 30(47): 5055. CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro Hepatology Research.2023; 53(2): 104. CrossRef
Metabolic-associated fatty liver disease and the risk of cardiovascular disease Pengwei Zhang, Xianhui Dong, Wei Zhang, Shiyin Wang, Chen Chen, Jiake Tang, Yao You, Siqi Hu, Shenghui Zhang, Chunyi Wang, Wen Wen, Mengyun Zhou, Tao Tan, Guanming Qi, Li Li, Mingwei Wang Clinics and Research in Hepatology and Gastroenterology.2023; 47(1): 102063. CrossRef
Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People Naoya Otsubo, Tatsuya Fukuda, Genhin Cho, Fumiaki Ishibashi, Tetsuya Yamada, Koshiro Monzen Internal Medicine.2023; 62(16): 2307. CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
New Concept of Fatty Liver: Metabolic dysfunction-associated fatty liver disease Takumi Kawaguchi Kanzo.2023; 64(2): 33. CrossRef
The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases Tsubasa Tsutsumi, Dan Nakano, Ryuki Hashida, Tomoya Sano, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Nutrients.2023; 15(5): 1123. CrossRef
MAFLD: How is it different from NAFLD? Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George Clinical and Molecular Hepatology.2023; 29(Suppl): S17. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives Shang-Chin Huang, Chun-Jen Liu Clinical and Molecular Hepatology.2023; 29(2): 320. CrossRef
How many times should we repeat measurements of the ultrasound-guided attenuation parameter for evaluating hepatic steatosis? Duck Min Seo, Sang Min Lee, Ji Won Park, Min-Jeong Kim, Hong Il Ha, Sun-Young Park, Kwanseop Lee Ultrasonography.2023; 42(2): 227. CrossRef
Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease Among Hospital Staff Daya Zhang, Lijun Zhang, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Feihu Bai Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 1221. CrossRef
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis Hong Fan, Zhenqiu Liu, Pengyan Zhang, Sheng Wu, Xinyu Han, Yiwen Huang, Yichen Zhu, Xingdong Chen, Tiejun Zhang Hepatology International.2023; 17(3): 615. CrossRef
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology Eileen Laurel Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(2): 371. CrossRef
Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease Jeong-Ju Yoo, Man Young Park, Eun Ju Cho, Su Jong Yu, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon Journal of Clinical Medicine.2023; 12(9): 3336. CrossRef
Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma Masafumi Ono, Koji Fujita, Kiyoyuki Kobayashi, Tsutomu Masaki Hepatology Research.2023; 53(7): 579. CrossRef
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study Eugene Han, Ho Soo Chun, Yong‐ho Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2023; 38(9): 1598. CrossRef
Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee Ultrasonography.2023; 42(3): 421. CrossRef
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma Byeong Geun Song, Sung Chul Choi, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik JHEP Reports.2023; 5(9): 100810. CrossRef
The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef
MAFLD: an optimal framework for understanding liver cancer phenotypes Harry Crane, Cameron Gofton, Ankur Sharma, Jacob George Journal of Gastroenterology.2023; 58(10): 947. CrossRef
Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study Ji Kim, Hee-Chul Nam, Chang-Wook Kim, Hee Cho, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Hyun Yang, Si Bae, Suho Kim, Jung Oh, Ho Chun, Chang Jeon, Jaegyoon Ahn, Pil Sung Cancers.2023; 15(17): 4233. CrossRef
What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez Current Hepatology Reports.2023; 22(4): 221. CrossRef
Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank Yu Jia, Dongze Li, Yi You, Jing Yu, Wenli Jiang, Yi Liu, Rui Zeng, Zhi Wan, Yi Lei, Xiaoyang Liao BMC Medicine.2023;[Epub] CrossRef
Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction‐associated fatty liver disease Kyu Yeon Choi, Tae Yeon Kim, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Jiwoo Lee, Mi Kyung Kwak, Eun‐Gyoung Hong, Yun Mi Choi, Yeonjung Ha Journal of Cachexia, Sarcopenia and Muscle.2023; 14(6): 2747. CrossRef
Ultrasonographic Assessment of Tissue Stiffness: Recent Progress in Transient Elastography and Shear Wave Elastography in the Liver and Various Organs MASAHITO NAKANO, RYOKO KUROMATSU, TAKUMI KAWAGUCHI The Kurume Medical Journal.2023; 70(1.2): 1. CrossRef
Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? Chi-Ho Lee Primary Care Diabetes.2022;[Epub] CrossRef
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura Clinical and Molecular Hepatology.2022; 28(2): 269. CrossRef
MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn, Kwan Sik Lee, Byoung Kwon Lee, Su Jung Baik, Seung Up Kim, Jung Il Lee Digestive Diseases and Sciences.2022; 67(10): 4919. CrossRef
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi, Mohammed Eslam, Shinobu Yoshinaga, Hirohiko Abe, Ryuichi Nouno, Seiya Joh, Keiichi Mitsuyama, Jacob George, Takuji Torimura Hepatology Research.2022; 52(8): 699. CrossRef
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients Susumu Inamine, Masayoshi Kage, Jun Akiba, Takumi Kawaguchi, Sachiyo Yoshio, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Ryuki Hashida, Kouichi Oshiro Hepatology Research.2022; 52(10): 841. CrossRef
MAFLD, patient-centred care, and APASL Shiv K. Sarin, Mohammed Eslam, Jian-Gao Fan, Han-Chieh Lin, Jacob George, Masao Omata Hepatology International.2022; 16(5): 1032. CrossRef
The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population Ji Yeon Seo, Eun Ju Cho, Min Joo Kim, Min‐Sun Kwak, Jong In Yang, Su Jin Chung, Jeong Yoon Yim, Ji Won Yoon, Goh Eun Chung Journal of Cachexia, Sarcopenia and Muscle.2022; 13(6): 2953. CrossRef
Fatty liver index as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years In-Ho Seo, Hye Sun Lee, Yong-Jae Lee Cardiovascular Diabetology.2022;[Epub] CrossRef
Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan International Journal of Molecular Sciences.2022; 23(23): 14762. CrossRef
Oidov Baatarkhuu, Hye Won Lee, Jacob George, Dashchirev Munkh-Orshikh, Baasankhuu Enkhtuvshin, Sosorbaram Ariunaa, Mohammed Eslam, Sang Hoon Ahn, Kwang-Hyub Han, Do Young Kim
Clin Mol Hepatol 2017;23(2):147-153. Published online May 2, 2017
Background/Aims Mongolia has one of the highest hepatitis A, C, B and D infection incidences worldwide. We sought to investigate changes in the proportion of acute viral hepatitis types in Mongolia over the last decade.
Methods The cohort comprised 546 consecutive patients clinically diagnosed with acute viral hepatitis from January 2012 to December 2014 in Ulaanbaatar Hospital, Mongolia. A time trend analysis investigating the change in proportion of acute hepatitis A virus, hepatitis C virus (HCV), hepatitis B virus (HBV) and hepatitis delta virus (HDV) infection among the cohort with respect to a previous published study was undertaken.
Results Acute hepatitis A, B and C was diagnosed in 50.9%, 26.2% and 6.0% of the cohort. Notably, 16.8% of the cohort had a dual infection. The etiologies of acute viral hepatitis were varied by age groups. The most common cause of acute viral hepatitis among 2-19 year olds was hepatitis A, HBV and superinfection with HDV among 20-40 year olds, and HCV among 40-49 year olds. Patients with more than one hepatitis virus infection were significantly older, more likely to be male and had a higher prevalence of all risk factors for disease acquisition. These patients also had more severe liver disease at presentation compared to those with mono-infection.
Conclusions Acute viral hepatitis is still prevalent in Mongolia. Thus, the need for proper infection control is increasing in this country.
Citations
Citations to this article as recorded by
Global burden and forecast of acute viral hepatitis B among women of childbearing age: a systematic analysis of the global burden of disease study 2021 Wei-dong Wu, Rui-xuan Li, Ding-qi Shi, Shah Dhruvi Chiragkumar, Yan-yan Gao, Jun-xiong Liu, Yao Xiao, Lei Si BMC Infectious Diseases.2026;[Epub] CrossRef
The working mechanism of biomarkers related to sumoylation modification in coronary artery disease Xiaowei Zhou, Fanyan Luo, Bitao Xiang, Kaixuan Li Scientific Reports.2025;[Epub] CrossRef
Hepatitis C Virus Infection in Mongolia: Updated Provincial Data on Prevalence, Genotype Distribution, and Age-Specific Risk Factors Amgalan Byambasuren, Myagmarjaltsan Baatarzorigt, Munkhtuya Otgon, Byambasuren Bat-Amgalan, Mandakhnaran Purevkhuu, Naranzul Nyamsuren, Enkh-Amar Ayush, Dashchirev Munkh-Orshikh, Khurelbaatar Nyamdavaa, Oidov Baatarkhuu Viruses.2025; 17(12): 1602. CrossRef
The Shifting Epidemiology of Hepatitis A in the World Health Organization Western Pacific Region Nina G. Gloriani, Sheriah Laine M. de Paz-Silava, Robert D. Allison, Yoshihiro Takashima, Tigran Avagyan Vaccines.2024; 12(2): 204. CrossRef
The burden of liver cancer in Mongolia from 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 Oyundari Batsaikhan, Odgerel Chimed-Ochir, Tatsuhiko Kubo, Chinburen Jigjidsuren, Vanya Delgermaa, Anuzaya Purevdagva, Amarzaya Sarankhuu, Erdenekhuu Nansalmaa, Uranchimeg Tsegmed, Badral Davgasuren, Oyuntsetseg Purev, Ali H. Mokdad, Nicole Davis Weaver, Frontiers in Oncology.2024;[Epub] CrossRef
Silent HDV epidemics culminates in high levels of liver cirrhosis in endemic region despite 20 years of HBV vaccination Olga V. Isaeva, Karen K. Kyuregyan, Anastasia A. Karlsen, Oleg V. Kuzmin, Ilya A. Potemkin, Vera S. Kichatova, Fedor A. Asadi Mobarkhan, Eugeniy V. Mullin, Tatyana V. Kozhanova, Victor A. Manuylov, Andrey A. Pochtovyy, Vladimir A. Gushchin, Anna A. Sarygl Journal of Viral Hepatitis.2023; 30(3): 182. CrossRef
Seroprevalence and risk factors of hepatitis B, C and D virus infection amongst patients with features of hepatitis in a referral hospital in Botswana: A cross-sectional study Sajini Souda, Julius C. Mwita, Francesca Cainelli, Naledi B. Mannathoko, Motswedi Anderson, Sikhulile Moyo Southern African Journal of Infectious Diseases.2021;[Epub] CrossRef
Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic Caterina Sagnelli, Mariantonietta Pisaturo, Caterina Curatolo, Alessio Vinicio Codella, Nicola Coppola, Evangelista Sagnelli World Journal of Gastroenterology.2021; 27(42): 7271. CrossRef
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission Graham S Cooke, Isabelle Andrieux-Meyer, Tanya L Applegate, Rifat Atun, Jessica R Burry, Hugo Cheinquer, Geoff Dusheiko, Jordan J Feld, Charles Gore, Max G Griswold, Saeed Hamid, Margaret E Hellard, JinLin Hou, Jess Howell, Jidong Jia, Natalia Kravchenko, The Lancet Gastroenterology & Hepatology.2019; 4(2): 135. CrossRef
Viral hepatitis among acute hepatitis patients attending tertiary care hospital in central India Pradip V. Barde, Vivek K. Chouksey, L. Shivlata, Lalit K. Sahare, Ashish K. Thakur VirusDisease.2019; 30(3): 367. CrossRef
A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection Yan Wang, Jeffrey S. Glenn, Mark A. Winters, Li-ping Shen, Ingrid Choong, Ya-lun Shi, Sheng-li Bi, Li-ying Ma, Hui Zeng, Fu-jie Zhang Diagnostic Microbiology and Infectious Disease.2018; 92(2): 112. CrossRef
First
Prev
